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SORAFENIB ENHANCES PEMETREXED CYTOTOXICITY THROUGH AN 
AUTOPHAGY-DEPENDENT MECHANISM IN CANCER CELLS  
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A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of 
Philosophy, Biochemistry and Molecular Biology at Virginia Commonwealth University. 
 
Virginia Commonwealth University, 2012 
 
Major Director: Dr. Paul Dent, Vice Chair of Research, Department of Neurosurgery 
  
 
Acquired cellular resistance to traditional chemotherapeutics is a common obstacle in the 
treatment of most cancer cell types.  This resistance occurs as a result of changes in the 
underlying molecular mechanisms of disease progression. The development of novel 
chemotherapeutic approaches designed to enhance the efficacy of protypical anti-cancer drugs is 
important in order to overcome this issue.  Such approaches will aid in understanding the 
biomolecular phenomena responsible for drug resistance and disease progression.  Combining 
signaling pathway inhibitors has become an effective strategy for enhancing tumor cell death by 
targeting multiple pathways known to regulate cell survival.  Pemetrexed, an FDA-approved 
anti-folate drug, targets thymidylate synthase (TS) and a secondary folate-dependent enzyme, 5’ 
aminoimidazole-carboximide ribonucleotide formyltransferase (AICART); both important for 
DNA synthesis.  Studies performed by our collaborator demonstrated that TS inhibition causes 
intracellular accumulation of ZMP+ and activation of AMPK which is known to induce 
 
xxiii
autophagy in mammalian cells.  Previous studies from our lab and others showed that sorafenib, 
a multi-kinase inhibitor of Raf-1 and class III receptor tyrosine kinases, was able to induce a 
cytotoxic form of autophagy in a variety of tumor cell types.  Combination treatment using 
pemetrexed and sorafenib in these cancer cells resulted in an enhancement of autophagy and cell 
lethality beyond that of individual drugs alone.  Inhibition of autophagy suppressed the toxic 
interactions of these drugs in all cell types examined.  Pemetrexed/sorafenib cotherapy also 
proved to be an effective treatment for triple negative breast cancer cells having advanced to a 
stage of estrogen independence.  Fulvestrant-resistant MCF7 cells were more sensitive to the 
drug combination than parental, estrogen-dependent MCF7 cells. Breast cancer cells cotreated 
with pemetrexed and sorafenib exhibited enhanced MEK/ERK signaling, Src activation that was 
dependent on platelet-derived growth factor β (PDGFRβ) downregulation, elevated protein 
phosphatase 2A (PP2A) activity, and increased de novo ceramide synthesis.  Studies using a 
mouse model of experimentally-induced breast cancer validated drug combination effectiveness 
through inhibition of tumor growth, while no deleterious effects on normal tissues were observed.  
The data presented demonstrates that pemetrexed/sorafenib cotreatment augments 
chemosensitivity in both in vitro and in vivo systems.  Based upon these findings, a Phase I 
clinical trial involving pemetrexed and sorafenib in breast cancer patients with solid, recurrent 
tumors was begun in 2011.  In conclusion, this work strongly supports a promising therapeutic 
utility for the pemetrexed/sorafenib combination in treatment of various cancer cell types. 
 
 1
 
 
 
 
 
 
Chapter 1: Introduction on cancer cell signaling 
 
 
 
1.1 Cancer Cell Signaling 
The development of cancer is a concern for persons of all races and among all demographics.  
The 5 year survival rate for patients diagnosed with cancer as an average for all cancer cell types 
spanning the years 1999-2005 was 68%, up from 50% between the years of 1975-1977 (1).  The 
increase in survival rate is attributed to early diagnostic measures, as well as more efficient 
treatment regimens.  Breast cancer is the least discriminatory form of cancer, as it will affect 1 in 
8 women in every country in the world (2). Indeed, breast cancer is the second leading cause of 
cancer deaths in women, following lung cancer.  The 5 year survival rate for women with breast 
cancer has increased from 63% in the 1960s to 90% today (1).  The development of novel breast 
cancer treatments, in addition to the enhancement of current standards of treatment, has 
improved the outcome and extended survival rate for the ~200,000 patients diagnosed with 
breast cancer each year (1).  Characterization of cellular signaling pathways involved in 
carcinogenesis has encouraged the development of target-specific chemotherapeutic drugs and 
treatment strategies aimed towards counteracting disadvantageous alterations seen in tumor cells. 
 
From studies pertaining to the specific signaling mechanisms involved in the deregulation of 
cellular growth pathways, as well as studies involving loss of function of proteins triggering cell 
death; an understanding of cellular signaling networks yields a wealth of information concerning 
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the development, progression, and treatment of all cancer cell types. Both genetic and 
environmental factors promote the development of cancer.  Progression of cancer can be a result 
of epigenetic alterations in one or many of the signaling cascades that our cells rely upon. These 
alterations provide cells with a means of bypassing signals that result in cell death, as well as 
exploiting those that promote cell survival. Due to the inter-connectedness of cellular signaling 
networks, subsequent alterations in signal transduction pathways will occur as a compensatory 
mechanism to accommodate and stabilize these changes. 
 
1.1.1- MAPK signaling 
Mitogen-activated protein kinase (MAPK) signaling involves four separate, yet inter-connected 
pathways including extracellular-signal regulated kinases 1 and 2 (ERK1/2), extracellular-signal 
regulated kinase 5 (ERK5), c-Jun N-terminal kinase (JNK/ stress-activated protein kinase/SAPK), 
and p38 (Figure 1-1) (3-13).  Activation of these kinases induces a variety of cellular events such 
as cell survival, cell death, regulation of gene expression, metabolism, and changes in cell 
morphology.  Transmission of signal through any of the MAPK pathways is initiated by 
stimulation of upstream cellular membrane receptors, resulting in formation of specific adaptor 
protein complexes.  These signals are then transmitted through a sequential, 3-tiered MAP kinase 
cascade involving MAP kinase kinase kinase (MAP3K), MAP kinase kinase (MAP2K), and 
MAPK proteins (Figure 1-1).  Signaling through Erk1/2 is generally thought to produce a 
proliferative signal, but on occasion can promote cell death.  The Erk5 pathway promotes cell 
growth (14-15).  The JNK and p38 MAPK pathways are typically activated in response to 
cellular stress or pro-inflammatory cytokines such as tumor necrosis factor-α (TNFα) and 
interleukin 1β (IL-1β), and most often promote apoptosis (3,6,8,13).  All four MAPK pathways 
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have been shown to be activated in response to radiation and chemotherapy-based treatments 
(16).  In the case of Erk1/2, growth signals such as those from the epidermal growth factor 
(EGF) receptor lead to activation of Raf family proteins (A-Raf, B-Raf, C-Raf/Raf-1), which 
serve as the MAP3K component of this cascade.  Ras proteins are usually activated prior to 
stimulation of Raf family protein members (17).  Regarding signals transmitted through 
activation of Ras, a guanosine triphosphatase (GTPase) bound to guanosine diphosphate (GDP) 
in its inactive form, GDP is exchanged for guanosine triphosphate (GTP) in response to growth 
promoting stimuli (7,18).  The complete mechanism by which Raf becomes activated by Ras is 
not fully understood (19).   
 
 
 
Figure 1-1:  MAP kinase signaling pathways.  Upon stimulation by a diverse array of 
extracellular and intracellular signals, pathways promoting both cell survival and cell death 
activate specific signaling through one of the four MAP kinase pathways.  These pathways 
involve a sequential, 3-tier kinase cascade through MAPKKK (MAP3K), MAPKK (MAP2K), 
and finally one of the four MAPK proteins.  Erk1/2, Erk5, JNK, and p38 MAP kinase pathways 
transduce signal to promote responses such as cell proliferation, cell differentiation, migration, 
apoptosis, and inflammation. 
 
Raf protein kinases serve as the MAP3K component of the Erk1/2 MAP kinase signaling cascade 
(7-8,20).  B-Raf is the substrate with the greatest affinity for Ras, therefore making it more 
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efficiently activated than the other Raf protein kinases (20).  For this reason it is understandable 
that B-Raf mutations, predominantly the activating V600E mutation, have the highest level of 
incidence in cancer amongst the Raf protein family members (21).  In recent years, Raf kinases 
were shown to have the ability to form homo and heterodimers, as well as be controlled by their 
association with inhibitory proteins such as Raf kinase-inhibitory protein (RKIP), 14-3-3, and 
connector enhancer of kinase suppressor of Raf-1 (CNK) (22).  MAPK signaling is mediated by 
adaptor protein complexes which enable its specific localization within the cell for precise 
communication of function to downstream targets.  Raf can also be regulated by protein 
phosphatase 2A (PP2A), which dephosphorylates the Ser259 residue of Raf, leading to its 
activation.  Signal transduction through Raf is relayed to mammalian homologue of STE11 
kinases 1 and 2 (MEK1/2) through phosphorylation of two serine residues (Ser218 and Ser222) 
in the activation loop of the protein (23).  Full activation of MEK1/2 is achieved only when acted 
upon by both Raf1 and p21-activating kinase 1 (PAK1) (24-25).  Active MEK1/2 binds to 
inactive Erk1/2 resulting in phosphorylation of threonine and serine residues within their 
phosphorylation loop.  Once activated, Erk1/2 is released from its association with MEK1/2 
enabling dimerization and translocation to the nucleus where it phosphorylates transcription 
factors and other kinases (26).  Erk1/2 also has additional targets in the cytoplasm including 
other kinases and cytoskeletal proteins (27-28).  In total, Erk1/2 is thought to have over 100 
potential substrates which provide for a diverse variety of cellular functions (Figure 1-2).  While 
it is generally accepted to be a transducer of proliferative signals, evidence also suggests that it is 
upregulated upon treatment with various chemotherapeutic drug regimens (29-31).  Protein 
phosphatase PP2A is also known to regulate MEK1/2 and Erk1/2 function by inactivating these 
enzymes when targeted, thus indicating a complex role for PP2A in this signaling pathway. 
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Ras/Raf/MEK/Erk is the most commonly dysregulated MAP kinase pathway identified in cancer.  
In fact, Raf-1 was the first serine/threonine kinase to be identified as oncogenic (32).  A 
multitude of Raf-related signaling events which promote cancer development and progression 
have been reported in the literature.  K-Ras and Raf activation has been shown to induce 
expression of mouse double minute-2 (mdm2), an inhibitor of tumor suppressor protein p53 
(TP53), resulting in enhancement of cell growth (33).  Upregulation of nuclear factor-kappa B 
(NF-κB) or cyclooxegenase-2 (Cox-2) expression mediated by Raf-1 provides growth survival 
advantages to tumor cells (34-35).  Oncogenic forms of Raf demonstrate resistance to 
radiotherapy and chemotherapy in some tumor types, thus protecting the cells from a common 
means of treatment for these diseases (36-38).  In some tumors, the B-Raf V600E mutant 
disrupts Erk-mediated activation of tumor suppressor liver kinase B1 (LKB1) by AMP-activated 
protein kinase (AMPK) preventing its restrictive limitations on protein translation (39).  On the 
other hand, Erk1/2 can also act as an antagonizing factor for cancer growth.  In human hepatoma 
cell lines, HepG2 and Huh7, doxorubicin or cisplatin treatment leads to Erk1/2 activation and 
cell death (40).  Activation of Erk1/2 following cisplatin treatment has also been shown to play a 
role in drug-induced apoptosis in HeLa human cervical carcinoma cells (41).  Additionally, in 
MCF-7 breast cancer cells, tamoxifen treatment induced sustained activation of Erk1/2 and drug-
induced cell death (42).  These specific examples are but a few of the many ways that signaling 
through the Ras/Raf/MEK/Erk pathway regulates cancer pathogenesis, as well as cancer 
treatment.  For these reasons, the Erk1/2 pathway is of major interest in cancer studies.  
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Figure 1-2:  A general overview of the MEK/Erk signaling pathway.  The ERK1/2 signaling 
pathway is initiated through activation of G-protein coupled receptors (GPCRs), receptor 
tyrosine kinases (RTKs), integrin receptors, and ion channels by their respective ligands.  
Activation of these pathways leads to recruitment of adaptor protein complexes which transduce 
signal to the MEK/Erk MAP kinase cascade via a variety of proteins.  This figure illustrates a 
general scheme by which these events occur, as there are many different mechanisms and 
signaling proteins identified to be involved.  In some cases, the GTPase K-Ras may be 
stimulated to serve as an upstream activator of the MAP3K component of this pathway (Raf 
family members).  Raf proteins phosphorylate and activate MEK1/2 (MAP2K) for subsequent 
activation of Erk1/2 (MAPK).  Erk1/2 phosphorylates over a hundred documented downstream 
targets, located in both the cytoplasm and the nucleus, to promote cell survival, proliferation, 
translation, differentiation, tumorigenesis, and migration. 
 
The Erk5 MAPK is stimulated by cytokines and proliferative mitogenic signals such as EGF, 
lysophosphatidic acid (LPA), neurotrophins, and phorbol ester; while some evidence suggests 
that it can also become activated in response to stress signaling molecules such as hydrogen 
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peroxide (H2O2), sorbitol, and ultraviolet irradiation (4,10,43).  MEKK2 or MEKK3 (MAP3K) 
phosphorylate MEK5 (MAP2K) for subsequent activation of Erk5 (MAPK).  Downstream 
targets of Erk5 include forkhead box O 3a (FoxO3a) and B cell lymphoma 2 (Bcl-2)-associated 
death promoter (BAD) proteins.  Activation of these proteins by Erk5 causes them to be 
sequestered in the cytoplasm, preventing their translocation into the nucleus and mitochondrial 
membrane, which promotes anti-apoptotic events (43). 
 
The p38 and JNK MAP kinases are the last of the family of MAPK proteins which are generally 
thought to be activated in response to stress stimuli.  Signaling through p38 and JNK pathways is 
stimulated by growth factors, environmental stresses, and inflammatory cytokines (44).  The 
JNK and p38 pathways have been shown to play a role in immune response, tissue homeostasis, 
cell death, cell migration, cell survival, and cell differentiation (45-47).  p38 kinases constitute a 
group of MAPK proteins including p38α (MAPK14), p38β (MAPK11), p38γ 
(SAPK3/Erk6/MAPK12), and p38δ (SAPK4/MAPK13) (48-52).  Each is encoded from a unique 
gene transcript and family members share 60% homology to one another, although they are 
thought to have different tissue-type specific expression patterns (53).  Likewise, JNK proteins 
constitute a group of three distinct MAP kinases termed JNK1 (MAPK8), JNK2 (MAPK9), and 
JNK3 (MAPK10).  JNK family protein members arise from spliced variations of the same gene 
transcript.  JNK1 and JNK2 are expressed in almost all cells, while JNK3 is primarily expressed 
in the brain (44,47).  p38 and JNK are activated by numerous kinases and are involved in a 
variety of cellular functions (44,47-48).  For both the p38 and JNK pathways, transmission of 
signal from upstream events leads to the activation of their MAP3K  kinases including apoptosis 
signal-regulating kinase 1 (ASK1), MEKK1, MEKK2, MLK1, MLK2, and MLK4 (44,48).  
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MKK7 and MKK4 (JNK) or MKK3 and MKK6 (p38) serve as the MAP2K components of these 
pathways.  MKK4 can also serve as an activating kinase for p38α by way of association with 
alternative signaling complexes (47,54).  p38 and JNK signal to cytoplasmic and nuclear 
downstream effectors which stimulate events associated with immunity, growth, differentiation, 
migration, and apoptosis (45-47) (Figure 1-1).  p38 activates multiple transcription factors, as 
well as numerous proteins kinases (55-56).  JNK was found to phosphorylate several targets 
promoting apoptosis such as 14-3-3, (Bcl-2-associated X protein) BAX, (Bcl-2-associated death 
promoter) BAD, caspase-8 and (Fas-associated protein with death domain) FADD-like apoptosis 
regulator (FLIP).  JNK can also promote caspase-8 independent cleavage of BH3-interacting 
domain death agonist (BID) (57-61). 
 
Both p38 and JNK pathways have been implicated in development of cancer.  The most well 
documented correlation to this disease is a loss-of-function mutation in MKK4 (44).  MKK4 is a 
putative tumor suppressor protein and loss-of-function mutations are found in 5% of pancreatic, 
lung, colon, breast, and prostate tumors (57).  p38 induced activation of Snf-2 related CREB-
binding protein-activator protein (SRCAP) promotes p53-dependent transcription of DNA 
damage proteins, indicating a tumor suppressive function for p38 (54).  JNK was shown to 
negatively regulate tumor suppressor p53, thus promoting cell growth.  Constitutively active 
forms of JNK1 also promote cell growth in vivo (61).  JNK and p38 proteins regulate the activity 
of proteases involved in inflammation and pro-inflammatory cytokine production, suggesting 
possible roles for these proteins in cancer, as chronic inflammation is a well-documented cause 
of cancer development (62).  Signaling through these pathways is very complex due to multiple 
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factors by which these pathways can communicate.  For each, pro-survival and pro-death 
responses can occur, dependent on the specific interactions of the signaling proteins involved. 
 
1.1.2 PI3K/Akt signaling 
Signals transduced through receptor tyrosine kinases (RTKs), integrins, and G-protein-coupled 
receptors (GPCRs) can lead to activation of the phosphoinositide 3-kinase (PI3K) pathway (63-
67).  The PI3K pathway is most commonly noted for promoting pro-growth/survival responses 
and it is one of the best studied pathways in the cell.  PI3K/ protein kinase B (Akt/PKB) 
signaling is involved in a vast array of cellular events including maintenance of homeostasis, 
glucose and lipid metabolism, cell growth, cell death, autophagy, neuronal function, structural 
organization, proliferation, angiogenesis, and migration (68) (Figure 1-3).  PI3K is a heterodimer 
compromising a catalytic subunit (p110) and a docking subunit (p85).  Upon stimulation of the 
upstream activating kinases, the enzymes associate with the p85 subunit of PI3K through the 
recruitment of adaptor proteins coordinated by their Src homology 2 (SH2) domains.  
Phospholipids located within lipid rafts on the plasma cell membrane are recruited to this 
complex and serve as targets for PI3K phosphorylation.  Phospholipid substrates for PI3K 
include phosphoinositide phosphate {PI(4)P} and phosphoinositide diphosphate {PI(4,5)P2} (69-
71).  The phospholipid products of these PI3K events include {PI(3,4)P2} and {PI(3,4,5)P3}, 
respectively (69-72).  PI3K activity can be counteracted by phosphatase and tension homolog 
(PTEN), which catalyzes the removal of a phosphate group from the 3 position of the 
phospholipids; therefore making PTEN a negative regulator of PI3K.  PI(3,4,5)P3 recruits 
downstream targets for PI3K such as phosphoinositide-dependent kinase-1 (PDK1), and Akt via 
their pleckstrin homology (PH) domains (63,69-70). 
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Akt is a multi-domain protein composed of 3 conserved domains: an amino-terminal PH domain, 
a central kinase domain, and a carboxyl-terminal regulatory domain for mediating its interactions 
with other proteins. Akt exists as three isoforms Akt1 (PKBα), Akt2 (PKBβ), and Akt3 (PKBγ).  
Almost all cell types express at least one isoform, while AKT2 and AKT3 are generally thought 
to be expressed in a tissue type-specific manner (73-74).  The association of PI(3,4,5)P3 and its 
PTEN breakdown product PI(4,5)P2 with Akt enables localization of PDK1 to the plasma 
membrane for activation of Akt by phosphorylation of Thr308 (75).  Akt activity is also 
modulated by phosphorylation at Ser473.  PDK1 is the primary activating kinase for Akt Thr308; 
however phosphorylation of Ser473 is necessary for its full activity (69).  Several kinases have 
been reported to phosphorylate Ser473 including mammalian target of rapamycin (mTOR) 
(when bound in the mammalian target of rapamycin complex 2/ TORC2 complex/ TORC2), 
PDK1, integrin-linked kinase (ILK), DNA-dependent kinase, and Akt itself (70-74).  The action 
of phosphatases is one of the many means by which Akt is regulated.  A phosphatase known to 
regulate Akt activity is PH domain leucine-rich repeat protein phosphatase (PHLPP), which 
exists as two isoforms that both specifically attenuate Akt activity through dephosphorylation of 
Ser473 (74,81).  Additionally, the serine/threonine phosphatase PP2A dephosphorylates Akt 
residue Thr308 (74).  Much like the MAPK/Erk signaling network, the PI3K/Akt pathway 
possesses over 100 known targets exhibiting a variety of cellular outcomes (82) (Figure 1-3). 
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Figure 1-3:  A general overview of PI3K/Akt pathway signaling.  AKT is activated by growth 
factors, cytokines, mitogens, and hormones.  Receptor activation leads to the recruitment and 
activation of PI3K to promote generation of PI(3,4,5)P3 on the plasma membrane.  PI(3,4,5)P3 
(PIP3 as illustrated in this figure) forms a complex with PDK1 and AKT via interactions with 
their PH domains resulting in activation of AKT Thr308.  Full activation of Akt also requires 
phosphorylation at Ser473.  PTEN serves as a negative regulator of PI3K activity by 
dephosphorylating PIP3 to generate PI(4,5)P2 (PIP2 as illustrated in this figure).  Akt is also 
known to have over a hundred downstream effector proteins found within the cytoplasm.  Akt 
serves as a critical regulator of many cellular functions including metabolism, translation, 
proliferation, survival, and angiogenesis. 
 
One critical function of Akt signaling is regulation of glucose uptake in insulin-responsive cells.  
Akt enhancement of glucose transport into the cell is a result of translocation of insulin-regulated 
glucose transporter 4 (GLUT4) to the plasma membrane.  Expression of constitutively active Akt 
(caAkt) enables translocation of GLUT4 to the plasma membrane in the absence of insulin, while 
overexpression of dominant negative Akt (dnAkt) demonstrated a reduction in insulin-stimulated 
glucose uptake in these cells (74).  In addition, Akt can activate a positive feedback mechanism 
by phosphorylation and inactivation of protein tyrosine phosphatase 1B (PTP1B), a negative 
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regulator of the insulin receptor (IR) (83).  Akt signaling also mediates glucose metabolism by 
phosphorylating glycogen synthase kinase 3 (GSK-3) at Ser21, preventing its inhibitory effects 
on glycogen synthase.  This event enables the conversion of glucose into glycogen for cellular 
storage (84). 
 
Akt acts as a positive mediator of angiogenesis by promoting both direct and indirect activation 
of pro-angiogenic events.  Direct activation of endothelial nitric oxide synthase (eNOS) at 
Ser1777 by Akt was found to promote migration of endothelial progenitor cells (EPCs) from the 
bone marrow to the vascular endothelium in vivo (85).  Akt activity was found to correlate with 
the activities of vascular endothelial growth factor (VEGF), vascular endothelial (VE)-cadherin, 
and endothelium-specific receptor tyrosine kinase 2 (Tie2) receptors in vivo (86).  Little is 
known about the mechanisms by which Akt indirectly stimulates pro-angiogenic events. 
 
Cell growth and survival are considered to be the major cellular outcomes of Akt signaling.  
Downstream effectors for Akt known to promote these events include IκB kinase (IKK), mTOR, 
cyclin-dependent kinase inhibitors (p21WAF1/CIP1, p27KIP1), BAD, ASK1, and forkhead box O 
(FoxO) subfamily transcription factors (87-92).  When active, IKK phosphorylates IκB leading 
to activation of nuclear factor kappa-light-chain-enhancer of B (NFκB), a transcription factor 
promoting expression of numerous pro-survival proteins.  Phosphorylation of BAD, a pro-
apoptotic Bcl-2 family member, results in the release of BAD from its inhibitory association with 
anti-apoptotic Bcl-2 family members which bind 14-3-3 proteins to promote cell survival (93-94).  
Akt signaling promotes phosphorylation of several cell cycle inhibitors to prevent them from 
restricting cell growth. 
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mTOR is the best-studied substrate for AKT phosphorylation.  Akt activates mTOR through 
direct phosphorylation of Ser2448, as well as through phosphorylation and inactivation of 
tuberous sclerosis-2 (TSC2).  Inactivated TSC2 allows the GTPase Rheb to remain in its GTP-
bound state making mTOR available for activation (95).  mTOR may be associated with 2 
different signaling complexes: TORC1, through association with regulatory associated protein of 
mTOR (Raptor) and mLST8; or TORC2, through association with rapamycin insensitive 
companion of mTOR (Rictor), stress-associated protein kinase interacting protein 1 (Sin1), 
mTOR-associated protein LST8 homolog (mLST8), and protein-associated with Rictor 1 and 2 
(PROTOR1/2) (Figure 1-4) (95).  Phosphorylation of insulin receptor substrate protein 1 (IRS1) 
by insulin and insulin-like growth factors (IGFs) leads to IRS-1 association with PI3K, 
promoting PDK1 activation of Akt and cell growth (96).  Bound within the (TORC1) complex, 
mTOR activates S6 kinase-1 (S6K1) leading to activation of ribosomal protein S6 and increased 
protein translation.  Another means by which activated mTOR (TORC1) can enhance protein 
translation is through activation of eukaryotic translation initiation factor 4E binding protein 1 
(4EBP-1) which then recruits eukaryotic translation initiation factor 4E (eIF-4E) (97-98).  Active 
mTORC1 and S6K can target insulin receptor substrate 1 (IRS-1) to provide a negative feedback 
mechanism for these events (68,73).  Additional signaling involving mTOR will be detailed 
further in later sections as mTOR plays a critical role in the studies to be discussed.   
 
 
 14
 
Figure 1-4:  Akt regulation of mTOR, a component of TORC1 and TORC2 complexes.  Akt 
is a direct and indirect regulator of mTOR.  Akt indirectly regulates mTORC1 through 
phosphorylation of TSC2, dissociating it from TSC1, enabling GTP hydrolysis of Rheb for 
subsequent activation of mTOR.  mTORC1 can activate multiple downstream effectors, most 
notably S6 kinase (S6K1) and 4EBP-1 to promote protein translation.  mTORC1 also targets 
PP2A which aids in the regulation of 4EBP-1.  Akt activation of mTOR bound within the 
mTORC2 complex leads to the activation of Rac, Rho, and PKC to stimulate cytoskeletal 
rearrangement.  
 
The PI3K/Akt pathway contributes to cell growth, cell survival, cell migration, and angiogenesis; 
therefore it should come as no surprise that alterations in this pathway contribute significantly to 
the development and progression of cancer.  Typically, signaling within the PI3K/ Akt pathway 
is highly active in tumor cells, yielding cells a growth and survival advantage.  This pathway is 
also a factor in cellular resistance to chemotherapy and radiotherapy (98).  A point mutation 
within the p110 kinase domain of PI3K is the most common Akt pathway-associated 
dysregulatory event found in cancer (98-100).  This mutation occurs frequently in Her2+ breast 
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cancers, while they have also been noted in bowel, ovarian, head and neck squamous, cervical 
squamous, gastric, lung, brain, and medulloblastoma cancers (98-106).  mTOR, a major target of 
Akt, is commonly activated in transformed cells.  Inhibitors of mTOR have been approved for 
treatment of renal cell carcinoma, while clinical trials are in progress for treatment of 
glioblastoma and metastatic breast cancer cells (107-109).  PTEN loss of function is another 
common factor in tumor cell pathogenesis and is most prevalent in brain, breast, thyroid, prostate, 
and endometrial carcinomas (98,110-112).  Amplifications or mutations within Akt have low 
prevalence in cancer, some rare sporadic cases have been reported for gastric, pancreatic, breast, 
and colorectal cancers (98,113-114).  PDK1 mutations are also rare, while some cases have been 
documented in colorectal cancer patients (98). 
   
1.1.3 AMPK/ LKB1/ mTOR signaling 
AMP-activated protein kinase (AMPK) is a major regulator of cellular homeostasis by 
stimulating events related to cellular metabolism and adenosine triphosphate (ATP) production.  
This pathway is activated in response to several stimuli including low intracellular ATP levels, 
low intracellular Ca2+ levels, hypoxia, ischemia, and heat shock (115).  The AMPK protein 
complex consists of 3 subunits: a catalytic subunit (α), a glycogen-sensing subunit (β), and a 
regulatory subunit (γ) containing 2 allosteric adenosine monophosphate (AMP) binding sites 
(115-117).  AMPK is activated by phosphorylation on its Thr172 residue which is located within 
the β subunit.  There are multiple sites shown to be phosphorylated within its activation loop, 
while the mechanisms by which these residues become phosphorylated are currently poorly 
understood (116).  Three upstream kinases have been reported to phosphorylate AMPK Thr172: 
liver kinase B1 (LKB1), calmodulin-dependent kinase kinase β (CaMKKβ) and transforming 
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growth factor β-activated kinase-1 (Tak1) (118-121).  Tumor suppressor LKB1 is considered to 
be the major activating kinase for AMPK Thr172 (122-123).  LKB1 can be activated by AMPK 
kinases STE20-like pseudokinase (STRAD) and a homologue of mouse protein 25 (MO25) (124).  
The AMPK pathway activates several downstream targets in an effort to restore intracellular 
energy and nutrient levels.  Some of the targets for AMPK include glycogen synthase, acetyl 
CoA carboxylases 1 and 2 (ACC1/2), HMG CoA reductase (HMGR), 6-phosphofructokinase 2 
(PFK-2), eukaryotic elongation factor 2 (eEF2), TSC2, Raptor, mTOR, interferon regulatory 
factor 1 (IRF-1), and sterol regulatory element-binding protein 1 (SREBP-1) (Figure 1-5) 
(116,125-128).  Signaling through these targets promotes ATP-generation, while inhibiting ATP-
requiring mechanisms in order to restore optimal energy and nutrient levels (116,125-128). 
 
AMPK maintains energy levels primarily through regulation of glycogen and lipid metabolism 
(116,122-130).  AMPK negatively regulates proteins involved in glucose and lipid biosynthesis, 
as these are ATP-consuming events.  Proteins negatively regulated by AMPK include glycogen 
synthase, SREBP-1, TSC2, and TORC2 (131).  In cases where glucose levels within the cell are 
low, 5-aminoimidazole-3-carboxamide-1-β-D-ribofuranoside (AICAR) is converted into ZMP 
leading to activation of AMPK and translocation of tissue-specific GLUT receptors to the plasma 
membrane to enhance glucose uptake (128-130,132).  Lipid metabolism is another means by 
which the cell restores energy levels.  Allosteric activation of AMPK by AMP negatively 
regulates lipid synthesis.  In energy-depleted cells with an elevated AMP:ATP ratio, AMPK 
signaling promotes lipid breakdown (Figure 1-5).  Lipid metabolism and biosynthesis occur 
throughout the cell and produce a variety of lipid molecules which have demonstrated 
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importance in nearly every cellular outcome (133).  These events will be discussed in further 
detail in a later section (Section 1.3). 
 
AMPK is also an important regulator of autophagy.  It coordinates autophagy through direct 
phosphorylation of multiple components within the mTORC1 pathway.  One such event involves 
the phosphorylation of Raptor on residues Ser722 and Ser792 which inhibits activity of this 
complex.  Evidence suggests that AMPK directly phosphorylates tumor suppressor TSC2 in 
nutrient-depleted conditions thus inactivating Rheb and preventing mTORC1 activation.  
Activation of AMPK by AICART can also lead to inhibition of mTORC1 activity (ref 134-135). 
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Figure 1-5:  The AMPK signaling pathway.  The AMPK pathway is the major pathway for 
maintaining cellular homeostasis.  AMPK signaling is stimulated by various cellular stress 
signals including low glucose, low oxygen, high AMP+, and high ZMP+ levels.  Low glucose 
results in the conversion of AICAR to ZMP+ for activation of AMPK.  Upstream activating 
kinases for AMPK include LKB1, CaMKKβ, and Tak1.  Active AMPK targets multiple 
downstream effector proteins.  ATP-requiring targets are negatively regulated by the actions of 
AMPK and these include TSC2, Raptor, mTOR, glycogen synthase, HMG CoA reductase, acetyl 
CoA carboxylase 1/2 (ACC1/2), and SREBP-1. Proteins activated by AMPK which stimulate 
ATP-generating events include IRF-1, eNOS, ULK1, p53, CREB, PFK2, and eEF2.   
 
 
The AMPK pathway is targeted for treatment of diseases such as obesity, type II diabetes 
mellitus, and multiple types of cancer (136).  Studies have shown that the AMPK pathway is 
dysregulated in breast cancers through a variety of molecular mechanisms causing down 
regulation of AMPK (137-138).  The AMPK pathway has also been implicated in malignant 
melanoma studies.  In these cells, the V600E B-Raf mutation enables hyperactivation of the 
MEK/Erk pathway and significant downregulation of AMPK signaling through inactivation of 
LKB1 promoting cell growth (139).  In lung cancer cells, attenuation of LKB1 activity enhances 
cell proliferation and metastasis in cells harboring mutant K-Ras (140).  AICAR activation of 
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AMPK was shown to exhibit anti-proliferative effects in malignant melanomas, while in lung 
cancer cells harboring wild-type LKB1, AICAR-activated AMPK promoted cell growth (141-
142).  AMPK activators have been suggested for treatment of ovarian cancers because these 
compounds sensitize these cells to glucose-deprived activation of AMPK (143).  The AMPK 
pathway acts to suppress cell growth and proliferation in energy-starved conditions which are 
common in tumor cells, making this pathway important in the treatment of multiple cancer types. 
 
1.2 Mechanisms of Cell Death 
1.2.1 Apoptosis 
There are two types of programmed cell death: Type I, apoptosis; and Type II, cytotoxic 
autophagy.  Type I, apoptosis, involves an energy dependent process that is controlled by the 
transcription and translation of proteins involved in DNA repair and regulation of cellular 
homeostasis. Propagation of this response can occur via the extrinsic or intrinsic pathways 
(Figures 1-6, 1-7).  The extrinsic cellular death pathway involves activation of receptors 
belonging to the death receptor subclass of the TNF receptor family such as CD95 (cell death 
receptor 95/APO-1/ Fas) and TNF-related apoptosis-inducing ligand receptor I (TRAIL/ DR4) 
(144).  These receptors are pre-associated homotrimers located within lipid rafts on the plasma 
cell membrane and, upon binding of their respective ligands, undergo a conformational change 
enabling binding of death domain adaptor proteins to form the death-inducing signaling complex 
(DISC) (Figure 1-6). The DISC complex is composed of the activated receptor bound to its 
respective ligand and the corresponding death domain-associated adaptor proteins, such FADD; 
which recruits and specifically binds to the effector caspase, procaspase-8 (145).  Upon its 
recruitment, procaspase-8 undergoes self-cleavage into its active form, caspase-8.  Caspase-8 
activation is suppressed by expression of cellular FLICE-like inhibitory protein 1 (c-FLIP-1) and 
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cellular FLICE-like inhibitory protein s (c-FLIP-s) (146).  Activated caspase-8 then can either: 
cleave BID to truncated-BID (tBID), which by way of the mitochondrial pathway leads to cell 
death; or directly lead to the cleavage and activation of caspase-3, promoting cell death.  
Caspase-3 may then translocate to the nucleus and deactivate DNA fragmentation factor-45 
(DFF45) through cleavage of the protein, disabling it from binding to and inhibiting the DNA 
fragmentation factor-40 (DFF40) enzyme.  DFF40, otherwise referred to as caspase-activated 
DNase, is then able to perform its enzymatic duty of DNA fragmentation, thus leading to a cell’s 
demise (147). 
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Figure 1-6:  The extrinsic and intrinsic apoptotic pathways.  Extrinsic apoptosis: In the case 
of the CD95 death receptor, a pre-associated homotrimeric CD95 complex binds extracellularly 
to its ligand (Fas-L) to promote and activating conformational change.  This change enables 
binding of its death domain adaptor protein (FADD) and formation of the death-inducing 
signaling complex (DISC) on the plasma cell membrane.  Procaspase-8 is recruited to this 
complex where is undergoes self-cleavage into its active form caspase-8.  Activation of caspase-
8 is inhibited by c-FLIP-1 and c-FLIP-s proteins.  Activated caspase-8 cleaves and activates 
caspase-3, enabling its translocation to the nucleus for dissociation of the DFF40 nuclease from 
its inhibitor, DFF45, resulting in DNA fragmentation and cellular death.  Intrinsic apoptosis: 
Activated caspase-8 can also cleave BID into its active form tBID.  Once activated, tBID 
translocates to the mitochondria to associate with other pro-apoptotic Bcl-2 family member 
proteins (Bax, Bak) to promote mitochondrial membrane permeabilization and the release of 
factors AIF and cytochrome c.  Cytochrome C forms a complex with Apaf-1 and procaspase-9 to 
promote activation of caspase-9.  Caspase-9 then activates caspase-3 for translocation to the 
nucleus for promotion of DNA fragmentation and eventual cell death. 
 
The intrinsic apoptosis pathway involves intracellular insults which promote activation of pro-
apoptotic Bcl-2 family member proteins (Figure 1-6) (148).  The mitochondrial component of the 
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extrinsic pathway is termed the intrinsic apoptosis pathway.  Extrinsic apoptotic pathway events 
leading to the cleavage of BID into its active form, tBID, by caspase-8 enables its translocation 
to the mitochondrial membrane.  tBID associates with  anti-apoptotic Bcl-2 family member 
proteins, causing their release from association on the outer mitochondrial membrane with Bax 
and Bak.  Bax and Bak then undergo conformational changes which enable permeabilization of 
the mitochondrial membrane and the release of factors, in particular cytochrome c, cytochrome c 
interacts with Apaf-1 and together, this complex causes activation of procaspase-9.  Active 
caspase-9 induces cleavage and activation of caspase-3 and eventual cell death (further described 
in Section 1.2.3) (145).  Inhibition of the intrinsic apoptosis pathway has previously been shown 
to suppress the cyto-toxicity of several thymidylate synthase (TS) inhibitors, including 
pemetrexed (149-150).  The intrinsic apoptotic events occurring at the mitochondrial membrane 
resemble the signaling events that take place in the case of autophagy-induced cellular death, 
Type II. 
1.2.2 Formation of the autophagosome 
Autophagy is a naturally occurring event which takes place in normal quiescent cells as a means 
of defense for clearing pathogens, as well as a mechanism by which the cell restores and 
maintains homeostasis (151-152).  Autophagy involves lysosomal degradation of non-vital 
cellular proteins and organelles, in order to recycle proteins back into their amino acid building 
block forms.  This process is activated by extracellular and intracellular insults resulting in 
elevated levels of reactive oxygen species (ROS), increases in intracellular Ca2+ levels, AICAR 
monophosphate (ZMP) accumulation, or energy and nutrient starvation (115-116).  Activation of 
autophagy occurs as a protective effort to restore energy and nutrient levels in an effort to restore 
homeostasis within the cell and promote survival (cytostatic autophagy).  Prolonged activation of 
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this signal, without restoration of the cell to an unstressed and unstarved state, can lead to 
induction of a cytotoxic form of autophagy.  Treatment of cells with anti-cancer drugs can cause 
prolonged cellular stress leading to the cytotoxic form of autophagy resultant of degradation of 
vital cellular contents (153-156).  Autophagic events are subdivided into 3 categories: micro-
autophagy, macro-autophagy, and chaperone-mediated autophagy (CMA) (153,156).  CMA 
involves the translocation of unfolded proteins directly through the lysosomal membrane for 
proteolytic degradation.  Direct engulfment of cytosolic proteins and organelles into the 
lysosome is described as micro-autophagy.  Once contained within the lysosome, proteins and 
organelles are degraded and recycled for the purpose of minimizing energy expenditure of non-
vital cellular components, as well as releasing nutrients back into the cell that are required for 
survival.  Macro-autophagy describes events where cellular components are first incorporated 
into the autophagosome prior to fusion with the endocytic lysosome (153-155,157-162).  This 
process is thought to be responsible for a majority of protein degradation occurring within the 
cell.  Macro-autophagy (hereafter referred to as autophagy) is mediated by two ubiquitin-like 
conjugation systems, autophagy-related genes 5-12 (Atg5-Atg12) and microtubule-associated 
protein 1 light-chain 3 (LC3/ATG8)- phosphotidylethanolamine (PE) (159-162).  Green 
fluorescent protein (GFP)-conjugated LC3, therefore serves as a useful tool for evaluating 
autophagosome formation in our tumor cell models.  The events responsible for formation of the 
autophagosome are important for the studies to be discussed in this dissertation because the data 
demonstrated significant enhancement of autophagosome formation, as judged by GFP-LC3+ 
vesicle formation. 
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Autophagy encompasses a series of events involving initiation of autophagosome formation, 
engulfment of non-vital cellular components, vesicle nucleation, vesicle expansion, Atg protein 
recycling, autophagosome fusion with the lysosome, and autolysosomal digestion of its contents 
to provide nutrients and amino acids for the cell (Figure 1-7) (160-162).  Two important proteins 
which regulate autophagy are mTOR and Bcl-2-interacting myosin like coiled-coil protein 
(Beclin1/Atg6) (153-154,161-162).  Beclin1 is the key initiator of autophagy in mammalian cells, 
while there is also some evidence to suggest that autophagy may be activated through Beclin1-
independent events (163).  When stimulated, Beclin1 is released from its association with anti-
apoptotic Bcl-2 family members Bcl-2, Bcl-2 protein 1 (Bcl-XL), and myeloid leukemia cell 
differentiation protein 1 (Mcl-1) to carry out its positive regulatory role in autophagy.  mTOR 
activation by PI3K/Akt serves as a negative mediator of these events by stimulating transcription 
and translation of anti-autophagic proteins, as well as directly binding to and inhibiting 
phosphorylated Atg proteins (164-165).  The core components of the autophagosome will be 
detailed in this section, while the specific molecular events that trigger an autophagic cellular 
response will be discussed in the next section (Section 1.2.3). 
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Figure 1-7:  Formation of the autophagosome by autophagy-related proteins.  Reduced 
PI3K signaling stimulates a sequence of events which results in formation of the autophagosome.  
There are two ubiquitin-like protease conjugation systems necessary for autophagosome 
formation to occur, the ATG5-12 (top half) and ATG8 (LC3)-phosphotidylethanolamine (PE) 
(bottom half) systems.  The ATG5-12 conjugation system involves a sequence of ubiquitin ligase 
events (E1- ATG7 and E2- ATG10) resulting in formation of a ATG5-12-16 trimer.  The trimer 
dimerizes to perform its function as the site of LC3 lipidation for membrane biogenesis.  The 
ATG8/ LC3-PE conjugation system begins with ATG4 cleavage of LC3 to expose a glycine 
residue where conjugation occurs.  ATG7 also serves as the E1 ubiquitin ligase for LC3 
conjugation, while the E2 ligase is ATG3.  After the E2 ligase step LC3 has affinity for PE on 
the plasma membrane, to which it binds.  Together, these events promote autophagy through 
initial formation of the autophagosome. 
 
 
Autophagic vesicle formation begins with the formation of the pre-autophagosome.  Atg17 
recruits Atg13 and Atg9 to activate a class III PI3K complex which includes class III PI3K 
protein 34 (Vps34), the p150 PI3K regulatory subunit, Atg14, Beclin1/Atg6, and ultraviolet-
irradiation resistance-associated gene (UVRAG).  Wortmannin, LY294002, and 3-methyladenine 
(3-MA) are small molecule inhibitors of the class III PI3K Vps67 and can be used to block 
induction of autophagy (166).  Events associated with this complex drive pre-autophagosome 
membrane nucleation by promoting the association of initial protein components (163).  
Elongation of the pre-autophagosome occurs by way of Atg5-Atg12 and LC3II-PE ubiquitin-like 
conjugation systems which are both localized to the PI3K complex.  Atg7 and Atg10 mediate the 
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covalent association of Atg5 with Atg12 (Atg5-Atg12), which interacts with Atg16 to promote 
elongation of the developing membrane.  This complex is later released and does not serve as a 
component of the mature autophagosome.  The LC3 (ATG8)-PE conjugation system associates 
with the pre-autophagosome and does serve as a component of the mature autophagosome.  LC3 
is cleaved to LC3-I by ATG4, then conjugated to phosphotidylethanolamine (PE) to generate 
LC-II through ATG3/ATG7-dependent events (154).  Once lipidated, LC3-II associates with 
Beclin1/ATG6 on the vesicle membrane and provides a means for recruitment of the cargo to be 
recycled.  Cargo adaptor proteins such as p62, next to breast cancer type 1 susceptibility gene 
protein 1 (Nbr1), and the proapoptotic Bcl-2 related protein Nix, mediate delivery of specific 
cargo to the autophagosome through direct and tight interactions with LC3-II.  Ubiquitination 
domains are located on cargo adaptor proteins and associate with ubiquitinated cargo for 
incorporation into the autophagosome.  Fusion of the mature autophagosome with acidic 
lysosomes is regulated by soluble n-ethylmaleimide sensitive fusion attachment protein 
(SNARE) proteins.  Proteinase B-1 (PRB1) and Atg15 lipase function to break down the 
autophagosomal vesicle leading to fusion with the lysome and formation of the 
autophagolysosome where degradation of cargo takes place (154). 
1.2.3 Regulation of Autophagy 
Type II cell death, a cytotoxic form of autophagy, involves downregulation of anti-apoptotic Bcl-
2 family member proteins Mcl-1 and Bcl-XL.  Deactivation is a result of disassociation with pro-
apoptotic members of the same family through interactions between their Bcl-2 homology 3 
(BH3) domains (Figure 1-8) (167-169).  Bcl-2 family members possess one to four Bcl-2 
homology domains (BH1-BH4) that mediate their interactions with other Bcl-2 homology 
domain containing proteins for regulation of specific downstream signaling events.  All Bcl-2 
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family members contain a BH3 domain (167).  Bcl-XL and Mcl-1 may bind to Beclin1 or BH3-
only proteins such as BID, Bcl-2-like protein 11 (BIM), BAD, p53 upregulated modulator of 
apoptosis (PUMA), and adult T cell leukemia derived PMA-responsive protein (NOXA).  These 
BH3-only proteins are sequestered by Mcl-1 and Bcl-XL away from the mitochondrial 
membrane (167,170).  Release of Beclin1 allows it to perform its function as an inducer of 
autophagy as described in the previous section.  Upon disassociation from Bcl-XL and Mcl-1, 
Bax and Bak undergo an activating conformational change and homodimerize to form pores with 
the mitochondrial membrane.  Pore formation allows for the release of pro-apoptotic signals 
from the mitochondrial inter-membrane space into the cytosol (171).  These signaling molecules 
include cytochrome c and apoptosis-inducing factor (AIF) which perform separate functions 
within the cytosol of the cell (Figure 1-9) (172-173).  AIF released into the cytosol can 
translocate to the nucleus to promote chromatin condensation and DNA fragmentation (174).  
When released, cytochrome c binds to Apaf-1, disassociating Apaf-1 from pro-caspase 9, 
enabling its self-cleavage and activation.  Activated caspase 9 may then cleave and activate 
caspase 3 (as mentioned in Section 1.2.1).  Caspase-3 then translocates to the nucleus for 
deactivation of DFF45 and release of the DFF40 DNase promoting DNA fragmentation and 
eventual cell death (175). 
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Figure 1-8:  Activation of autophagy via intracellular stress signaling.  Initiation of 
autophagy occurs as a response to cell stress and is regulated by a variety of factors.  Anti-
apoptotic Bcl-2 family member proteins (Bcl-XL and Mcl-1) interact with BH3-domain 
containing proteins (Bax and Bak).  Bax and Bak homodimerize to form pores on the 
mitochondrial membrane enabling the release of cytochrome C from the inner mitochondrial 
membrane space.  Cytochrome C binds to the Apaf1/procaspase-9 complex to promote cleavage 
of procaspase-9 for generation of active caspase-9.  Active caspase-9 cleaves and activates 
caspase-3 to promote cell death. 
 
 
1.3 Lipid Signaling in Cancer 
Lipids, while important for cellular membrane structure and integrity, have received an 
increasing amount of attention over the last two decades with regards to their roles in cellular 
signaling.  A majority of the signaling events found to be regulated by lipid molecules involve 
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sphingolipids.  Sphingolipids are ubiquitinously expressed in the membranes of mammalian cells 
and their metabolites possess potent biological activity.  Bioactive sphingolipid metabolites 
include sphingosine, ceramide, sphingosine-1-phosphate, and ceramide-1-phosphate (176).  
These molecules have been shown to play a role in numerous cellular processes including 
apoptosis, growth arrest, differentiation, inflammation, angiogenesis, intracellular trafficking, 
cell migration, and cell adhesion (177).  The enzymes responsible for sphingolipid biosynthesis 
and function are regulated by a complex set of cellular events, the specific mechanisms that 
control these enzymes remain to be elucidated (178).  Dysregulation of sphingolipid levels has 
implications in neurodegenerative disorders, metabolic diseases, and multiple cancer types.  
Enhanced lipid biosynthesis is an event commonly associated with cancer.  These phenomena are 
likely due to an enhanced need for lipids during cell membrane production, as well as an 
alternative means of energy production through β-oxidation and lipid modification of proteins 
(179).  For this reason, enzymes involved in the synthesis of sphingolipid molecules are of 
interest in development of novel chemotherapeutic drugs.  Generation of sphingolipids occurs 
through three primary mechanisms: sphingomyelin hydrolysis, the de novo ceramide synthesis 
pathway, and the salvage pathway.  Each mechanism involves sequential actions of multiple 
enzymes to generate each of the unique lipid moieties.   
 
1.3.1- Sphingomyelin hydrolysis 
Sphingomyelin hydrolysis involves the breakdown of lipid metabolites into ceramide.  
Biosynthesis of sphingomyelin is catalyzed by sphingomyelin synthase and involves the transfer 
of phosphocholine from phosphatidylcholine to ceramide, which occurs in the pre-Golgi 
membranes (180).  Sphingomyelin is then transported to the plasma membrane by vesicular 
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means to become an abundant outer lipid bilayer component.  During times of cellular stress 
often associated with tumor necrosis factor α (TNFα) stimulation, hypoxia, and 
chemotherapeutic drug exposure; sphingomyelinase enzymes (SMase) are activated to produce 
ceramide, a second messenger for apoptosis alongside receptor-mediated mechanisms.  This 
event occurs at the plasma membrane where sphingomyelin is abundant and is the primary 
means by which intracellular ceramide is produced (180).  Plasma membrane-associated SMase 
(neutral SMase) carries out the hydrolysis of sphingomyelin to form phosphocholine and 
ceramide.  Alkaline and acidic SMases are also present in cells.  However, these enzymes are 
cell type-specific or compartmentalized to specific subcellular locations where they carry out 
similar functions.  Ceramide is then available for promoting an apoptotic response or may be 
acted on by other enzymes involved in lipid biosynthesis to generate other sphingolipid 
derivatives.   
 
1.3.2- The de novo ceramide synthesis pathway 
The de novo ceramide synthesis pathway is more highly activated in cancer cells to 
accommodate the needs of rapidly proliferating tumor cells.  The de novo fatty-acid synthesis 
pathway takes place in the ER and is utilized to generate ceramide.  This process begins with the 
condensation of palmitate and serine to form 3-ketodihydrosphingosine which is catalyzed by 
serine-palmitoyl transferase.  3-ketodihydrosphingosine is then reduced to dihydrosphingosine 
by 3-ketoreductase.  At this point, dihydrosphingosine is acylated by dihydroceramide synthase 
to produce dihydroceramide (176-178,181-193).  Introduction of a 4,5 double bond in the 
sphingoid base of dihydroceramide by a specific dehydrogenase enzyme yields ceramide.  
Ceramide is then transported to the Golgi apparatus via the ATP-dependent ceramide transfer 
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protein (CERT) (194).  Once ceramide reaches the Golgi it is converted to sphingomyelin by 
SMase to become one of the major components of the outer bilayer of the plasma membrane 
(177,180,188-193,195).  Ceramide produced at the ER can also be acted upon by ceramidase to 
produce sphingosine, which may be converted into sphingosine-1-phosphate by sphingosine 
kinase.  In some cases, sphingosine-1-phosphate is further broken down into 
phosphatidylethanolamine and fatty aldehydes by a specific lyase enzyme (176,178,182,196-
197).  The de novo ceramide synthesis pathway has been implicated in induction of apoptosis 
upon treatment with numerous chemotherapeutic drugs in multiple tumor types including: 
glioblastoma, head and neck squamous cell carcinoma (HNSCC), renal cell carcinoma (RCC) 
and non-small cell lung carcinoma (NSCLC), chronic myeloid leukemia, neuroblastoma, 
gastrointestinal, breast, ovarian, and colon cancer cells (180-183,185-186,190-194,198-207).  In 
recent years, ceramide-activated serine/threonine protein phosphatases PP1 and PP2A, as well as 
inhibitory protein 2 of PP2A (I2PP2A/SET) were found to directly bind ceramides.  In the case 
of I2PP2A, ceramide binding prevents its inhibitory association with PP2A, thus activating the 
enzyme.  These serine/threonine phosphatase regulatory events were found to occur in multiple 
tumor types and promoted a tumor suppressive role for PP2A (177,194,208-210).  Recent studies 
have demonstrated activating roles for these synthetic sphingolipid molecules towards ceramide-
activated protein phosphatases and the onset of apoptosis (181,186,205,211).         
 
1.3.3- The lipid salvage pathway 
The salvage pathway takes place within the acidic late endosomes and lysosomes and accounts 
for 50%-90% of sphingolipid biosynthesis in the cell (178,184,187).  Production of sphingosine 
itself only occurs by way of the salvage pathway (187).  Acidic sphingomyelinase converts 
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sphingomyelin into ceramide, which can be further hydrolyzed into sphingosine and a long-chain 
free fatty acid.  Sphingosine and free fatty acids are then released from the lysosome, whereas 
ceramide is not.  The salvage pathway is typically thought of as the mechanism by which 
sphingosine is recycled and is often referred to as the recycling pathway.  Once sphingosine is 
released from the lysosome it can be converted into ceramide by the action of ceramide synthase, 
similar to the de novo ceramide synthesis pathway (178,184,187). 
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Figure 1-9:  The ceramide synthesis pathways.  The first step in this pathway involves the 
rate-limiting condensation of palmitate and serine to form 3-ketodihydrosphingosine, catalyzed 
by serine-palmitoyl transferase.  3-ketoreductase then reduces 3-ketodihydrosphingosine to 
dihydrosphingosine.  Dihydrosphingosine is acylated by dihydroceramide synthase to produce 
dihydroceramide.  Dihydroceramide desaturase introduces a 4,5 double bond in the sphingoid 
base of dihydroceramide to yield ceramide.  Ceramide is then transported to the Golgi apparatus 
for enzymatic conversion to sphingomyelin to become one of the major components of the outer 
bilayer of the plasma membrane.  Ceramide produced at the ER can also be acted on by 
ceramidase to produce sphingosine, which may be converted into sphingosine-1-phosphate by 
sphingosine kinase.  In some cases, sphingosine-1-phosphate is further broken down into 
phosphatidylethanolamine and fatty aldehydes by a specific lyase enzyme. 
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Chapter 2- Introduction on Chemotherapeutic Agents 
 
 
 
2.1 Combinatorial drug therapy for treatment of cancer 
 
Chemotherapeutic targeting of individual cellular signaling pathways is a highly effective 
method of treatment for cancer, yet there are many obstacles surrounding this approach.  One 
major example, resulting from prolonged administration of many of the Food and Drug 
Administration (FDA)-approved chemotherapeutic drugs is acquired drug resistance.  In cancer, 
resistance to anticancer drugs manifests through a variety of factors related to an individual’s 
genetics, as well as, intrinsic alterations in cellular signaling pathways which enable alternative 
mechanisms for bypassing drug toxicity (212).  One means of circumventing this obstacle is 
through use of a combination of chemotherapeutic agents chosen to specifically target two 
pathways simultaneously.  Molecular targeted combination drug therapies are designed to inhibit 
cell survival pathways, as well as stimulate cellular death signals/signaling.  A clinically relevant 
theory pertaining to treatment of tumor cells with multiple agents encompasses the thought that 
intended concentrations for each drug can be minimized to concentrations below that of 
clinically relevance, as a result of achieving a novel lethal effect.  Minimizing the concentrations 
of each drug should in turn minimize the levels of normal tissue toxicity. 
 
There are many combination drug therapies currently approved for treatment of a wide variety of 
cancer cell types.  There is also a growing number of targeted cotherapy trials reaching the clinic.  
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For example, a current Phase III trial for NSCLC patients involves ganetespib, a heat shock 
protein 90 (Hsp90) inhibitor, combined with docetaxol, paclitaxel, or another microtubule 
targeting agent.  And recently, a Phase III trial involving lapatinib and herceptin in early-stage 
breast cancer patients achieved a 51.3% pathological complete response, as compared to 
lapatinib (23.4%) and herceptin (21.1%) agents alone (213).  The combination of sorafenib, a 
class III receptor tyrosine kinase inhibitor, with Docetaxol and/or Letrozole is currently in Phase 
III clinical trials as an initial line of treatment for recurrent Her2-neu negative breast cancer 
patients (214).  With respect to pre-clinical studies, our lab and others have shown that sorafenib 
combined with histone deacetylase (HDAC) inhibitors causes synergistic cell killing in hepatoma, 
cholangiocarcinoma, and leukemia cells (215).  HDAC inhibitors also synergize with the cyclin-
dependent kinase (CDK) inhibitor flavopiridol in vitro to synergistically kill human leukemia 
cells through a mechanism involving suppression of the NF-κB pathway (216).  We have also 
shown that flavopiridol and vorinostat causes enhanced cell death in breast cancer cells, 
providing another promising clinical treatment option for these patients (217). 
 
2.2 Pemetrexed 
2.2.1- Anti-folates as chemotherapeutic agents 
Anti-folate compounds compromise a category of chemotherapeutic agents designed to suppress 
DNA and RNA synthesis.  Anti-folates have been utilized in the clinic for several decades with 
methotrexate being the most common.  Methotrexate was first identified as an analog of 
aminopterin (4-amino-folic acid) to more effectively inhibit DNA and RNA synthesis (218).  
Methotrexate was later found to specifically target dihydrofolate reductase (DHFR) (219).  The 
drug was FDA-approved for multi-drug treatment of acute lymphoblastic leukemia (ALL); as 
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well as the standard of treatment for rheumatoid arthritis (220-221).  In addition to these diseases, 
it has shown utility in the treatment of choriocarcinoma, osteosarcoma, non-Hodgkin lymphoma, 
head and neck, breast, and lung cancers (222).  In an effort to identify methotrexate analogs with 
greater affinity for DHFR that are less specific for normal tissue cells, studies identified 
pralatrexate (10-proargyl-10-deazaminopterin, Folotyn®), which was since approved for the 
treatment of relapsed peripheral T-cell lymphoma in 2009 (223).  In a unique effort to inhibit 
DNA synthesis, later studies were conducted to identify novel anti-folate compounds primarily 
targeting the thymidine and purine biosynthetic machinery, as opposed to DHFR.  Several of 
these compounds were initially identified (CB37175, Lometrexol), unfortunately, these drugs 
met with little success in the clinic (224-225).  Subsequent studies aimed towards synthetic 
analogs of Lometrexol, led to the discovery of Pemetrexed (PTX/ ALIMTA®) (226). 
Pemetrexed is a second generation anti-folate drug identified as targeting de novo thymidine and 
purine bio-synthetic enzymes.  In February 2004, pemetrexed was FDA-approved for treatment 
of malignant pleural mesothelioma (MPM) in combination with cisplatin for patients whom 
surgical resection is not an option (227-232).  In August of the same year, pemetrexed was 
approved as a single agent second-line therapy for locally advanced or metastatic non-squamous 
NSCLC.  It was approved for combination therapy with cisplatin as an initial line of treatment 
for the same disease in 2008.  The following year, it received approval as a single agent 
therapeutic route in non-squamous NSCLC after 4 rounds of treatment with platinum-based 
compounds (cisplatin, carboplatin, oxaliplatin) (229,233).  Pemetrexed has also entered the 
clinical setting for trials in a variety of other tumor types, including small cell lung carcinoma, 
breast, pancreatic, colorectal, esophageal, gastric, renal, head and neck, bladder, cervical, and 
ovarian cancers (234-239). 
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Pemetrexed is transported into the cell by the reduced folate carrier and protein-coupled folate 
transport systems.  Once transported into the cell, pemetrexed is polyglutamated by 
folylpolyglutamate synthetase enabling its retention in the cell for subsequent inhibition of its 
intracellular target(s).  Pemetrexed was originally developed as an inhibitor of thymidylate 
synthase (TS), but has subsequently been shown to target multiple enzymes involved in folate 
metabolism and purine and pyrimidine biosynthesis. 
2.2.2- Thymidylate Synthase (TS) as a primary target for Pemetrexed 
Pemetrexed was initially found to be an inhibitor of thymidylate synthetase (TS).  TS catalyzes 
the reductive methylation of deoxyuridine monophosphate (dUMP) into deoxythymidine 
monophosphate (dTMP) using N5,N10-methylene tetrahydrofolate as a co-factor which gets 
oxidized to yield the secondary product dihydrofolate.  Through successive phosphorylation 
events involving nucleoside monophosphate kinase and nucleoside diphosphate kinase, dTMP is 
converted into deoxythymidine-5’-triphosphate (dTTP or TTP) for use in DNA synthesis (240) 
(Figure 2-1).  TS is the rate-limiting enzyme in de novo thymidine synthesis.    Pemetrexed binds 
in the active site of TS to form an inhibitory complex preventing consequent steps which form 
dTTP (238,241).  Inhibition of TS causes a dramatic reduction in cell proliferation resultant of 
reduced DNA synthesis and cell death.  Inhibition of TS also causes an accumulation of dUMP 
because dUMP is a substrate for the TS reaction.  dUMP is then converted into deoxyuridine 5’ 
triphosphate (dUTP) by dUMP phosphatases (dUMPases) naturally present in the cell.  DNA 
polyermase allows for misincorporation of dUTP in sites where dTTP should be incorporated 
during DNA synthesis causing cell stress and eventual cell death; thus providing a secondary 
means of negative regulation by pemetrexed on cell proliferation and survival (242).  Patients 
with NSCLC who are non-responsive to pemetrexed were found to have elevated levels of TS, 
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indicating that TS is a potential predictive biomarker of drug effectiveness (238,242).  Based on 
the continued anti-proliferative effect upon cells in vitro in the presence of exogenous thymidine 
to prevent the cytotoxic effects of TS inhibition, it became apparent that pemetrexed has at least 
one secondary target (243-246). 
2.2.3- AICART is a secondary target for Pemetrexed 
In an effort to define additional targets of pemetrexed, our collaborators identified the folate-
dependent enzyme, aminoimidazole-carboxamide ribonucleotide formyl-transferase (AICART), 
as a secondary drug target (243-244).  AICART is the second folate-dependent enzyme in de 
novo purine biosynthesis (244) (Figure 2-1).  AICART catalyzes the reaction of 10-formyl-
tetrahydrofolate (THF) and 5-aminoimidazole-4-carboximide-1-β-D-ribofuranoside (AICAR) to 
formyl THF and formyl-AICAR.  This reaction follows the first step in de novo purine synthesis, 
which is catalyzed by phosphoribosylglycinamide formyltransferase (GART).  Both are essential 
steps in purine biosynthesis for cells not exposed to exogenous purines (247).  Supplementation 
of cells with a precursor of the product of the GART reaction, aminoamidazole carboxamide 
(AICAR), suggested AICART as a secondary target of pemetrexed.  The kinetic inhibitory rates 
of pemetrexed for AICART were later determined (244).  Inhibition of AICART results in 
elevated levels of 5-aminoimidazole-4-carboxamide ribonucleotide (ZMP), a substrate for 
AICART, to cause ER stress resulting in induction of autophagy.  Pemetrexed inhibition of 
AICART in NSCLC resulted in an intracellular accumulation of ZMP promoting activation of 
AMPK and downstream inhibition of mTOR (Figure 2-1) (243-244).  Suppression of mTOR 
promotes activation of autophagy by enabling the association of ATG proteins which is required 
to initiate formation of the autophagosome (248-249). 
2.2.4- Other known targets of pemetrexed 
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In addition to TS and AICART, several other secondary targets have been identified for 
pemetrexed.  AICART was identified more recently, while GART and DHFR were identified 
early in validation of the drug.  These enzymes are involved in de novo purine synthesis and 
pyrimidine metabolism (Figure 2-1).  Inhibition of DHFR by pemetrexed was shown to reduce 
the turnover of THF, a co-factor for the TS reaction, to further promote its growth inhibitory 
effects (237).  Pemetrexed binds to TS 60 times more tightly than to DHFR, making the effects 
of DHFR inhibition on TS activity nearly irrelevant (247).  GART, the primary target of 6R-
DDATHF, was originally identified as a secondary target of pemetrexed action.  However, 
studies aimed at determining the effects downstream of GART, led to the identification of 
AICART as the major enzyme within the de novo purine synthesis pathway targeted by 
pemetrexed (244).  The studies within this dissertation assume that the major toxic effect 
achieved by pemetrexed is that of TS and AICART inhibition.  For that reason, media for cell 
culture experiments is supplemented with dialyzed serum which does not contain exogenous 
thymidine for the purposes of mimicking the environment in humans/ patients, as well as 
elucidating the effect of TS inhibition. 
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Figure 2-1:  Mechanisms of pemetrexed toxicity in NSCLC cells.  Thymidylate synthase (TS) 
(red) is the primary target of pemetrexed (red).  Inhibition of TS prevents the production of 
dTMP from dUMP, therefore preventing the natural synthesis of thymidine for use in DNA 
synthesis.  AICART (red) was identified by our collaborators as a secondary target for 
pemetrexed, inhibiting the generation of formyl-AICAR from AICAR, thus inhibiting purine 
synthesis.  GART and DHFR (purple) have also been identified as secondary targets of 
pemetrexed, while inhibition of these targets requires significantly high concentrations of the 
drug to inhibit much lower levels of enzyme molecules per cell, as compared to TS and AICART.  
All other enzymes involved in thymidylate and purine synthesis (blue) have not been shown to 
be targeted by pemetrexed. 
 
2.2.5- Clinical relevance of Pemetrexed 
In addition to being approved for the treatment of non-squamous NSCLC and malignant pleural 
mesothelioma, pemetrexed has shown much success in clinic trials.  Pemetrexed in combination 
with other approved drugs compromise over 100 studies currently in clinical trials for various 
types of cancer; including advanced mammary carcinoma, metastatic colorectal carcinoma, 
squamous cell carcinoma of the head and neck, advanced urothelial carcinoma, and small and 
non-small cell lung carcinomas (250).  The drug is only issued to adults and its pharmacokinetics 
do not differ based on gender or race.  It is primarily excreted by the kidney and eliminated in the 
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urine due to a low extent of metabolism based according to studies examining patients with 
normal renal function (245).  The side effects seen in patients exposed to the drug can be severe.  
However, folate, vitamin B12, and sometimes corticosteroid supplements may be given to 
eliminate the toxic side effects of pemetrexed (227).  Pemetrexed has also proven successful 
when combined with radiation in treatment of pleural mesothelioma and NSCLC (246).  Due to 
the number of promising pemetrexed co-therapy treatment regimens in clinical trials, in addition 
to its success as a single agent, pemetrexed is a relatively safe and attractive option for 
development of novel chemotherapeutic strategies for the treatment of multiple types of cancer. 
2.3 Sorafenib 
2.3.1- Sorafenib for the treatment of multiple cancer cell types 
Sorafenib (Bay 43-9006, Nexavar®; a Raf family kinase inhibitor) is a dual-action drug 
developed for targeting Raf-1, an upstream activator of the MEK/Erk pathway.  Sorafenib was 
later shown to be a promiscuous inhibitor for multiple class III tyrosine kinase receptors (255-
263).  These growth factor receptor pathways, in addition to the Erk1/2 pathway, are responsible 
for cellular events including survival, proliferation, migration, differentiation, and angiogenesis.  
Many, but not all, studies have validated the effects of sorafenib on Raf-1 by illustrating 
suppression of Erk1/2 activation which correlated with reduced cell proliferation and 
angiogenesis.  These findings were demonstrated in several different cancer cell types including 
NSCLC, hepatoma, renal carcinoma, melanoma, colon, ovarian, and breast carcinoma cells (264-
269).  Sorafenib was FDA-approved for advanced renal cell carcinoma (RCC) in 2005 and then 
for inoperable, advanced hepatocellular carcinoma in 2007 (255).  There are numerous studies 
underway involving this drug as a single agent or in combination with another approved drug to 
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treat soft tissue sarcomas, recurrent glioblastomas, NSCLC, colorectal, pancreatic, thyroid, 
ovarian, and breast carcinomas (255).   
 
2.3.2- Sorafenib targets 
Sorafenib was originally developed as an inhibitor of Raf family kinases, primarily B-Raf and 
Raf-1, while the drug has a greater affinity for Raf-1.  Raf-1 serves as the MAP3K component of 
MEK/Erk1/2 pathway signaling, which is typically associated with pro-survival events. Down 
regulation of the Erk1/2 pathway is considered to be one mode of cell killing for the drug, due to 
Raf-1 inhibition.  In several tumor types, baseline Erk1/2 phosphorylation levels were shown to 
be a good predictive marker of sorafenib sensitivity, where higher basal levels of p-Erk1/2 is 
indicative of enhanced drug resistance (270).  In recent years, sorafenib-induced Raf-1 inhibition 
was demonstrated to also promote cell death in a MEK/Erk1/2-independent manner, possibly due 
to direct effects on apoptosis-regulating proteins or the combined effects of inhibition of 
alternative drug targets such as growth factor receptors (271-274).  In pancreatic carcinoma cells, 
sorafenib induced apoptosis occurred in MEK/Erk1/2-dependent and independent manners 
depending on the specific cell line being tested.  Treatment of skin, kidney, and liver carcinoma 
cells with sorafenib was shown to paradoxically activate ERK1/2 in tumors harboring wild-type 
BRAF (275-277).  These effects were shown to occur using low concentrations of sorafenib and 
were suggested to occur as a result of inhibition of a single Raf bound within a dimer, enabling 
transactivation of the adjacent Raf.  While the exact mechanism by which sorafenib carries out 
its toxic effects is based on the specific signaling pathway components present in each cell type, 
it is generally accepted that drug treatment results in inhibition of eukaryotic initiation factor 4E 
(eIF-4E) and downregulation of Mcl-1 (252,259,278-279).  Previous studies in our laboratory 
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and others have shown that sorafenib is toxic at concentrations well below the maximal 
achievable dose (~15 µM) using a mechanism involving down-regulation of Mcl-1.  This 
mechanism was shown to occur as a result of ER stress followed by activation of a cytotoxic 
form of autophagy (280-283).   
 
In addition to Raf family kinase members, sorafenib also targets multiple class III RTKs such as 
platelet-derived growth factor receptor α/β (PDGFRα/β), vascular endothelial growth factor 
receptors 1, 2 and 3 (VEGFR1, VEGFR2, VEGFR3), fibroblast growth factor receptor (FGFR), 
mast/stem cell growth factor receptor (c-Kit/ proto-oncogene c-Kit/ SGFR), and macrophage 
colony-stimulating factor-related tyrosine kinase 3 (FLT3/ FMS-related tyrosine kinase 3) (250-
257) (Figure 2-2).  Inhibition of the receptors mentioned above leads to suppression of 
angiogenesis at the tumor site, decreased cell proliferation, and reduced cell migration.  VEGFR 
signaling is one of the major means by which the cell mediates blood vessel maintenance and 
new vessel formation.  Thus, alterations in VEGF receptors signaling can promote growth of 
solid tumors which depend on angiogenesis to thrive, whereas untransformed cells remain in a 
state of vascular endothelial cell maintenance.  Sorafenib mediated inhibition of VEGFR2, which 
is the major VEGFR on the endothelial cell membrane, resulted in increased caspase-3 cleavage 
leading to apoptosis in RCC.  When sorafenib was combined with a murine double minute 2 
(mdm2) uncoupling agent (nutlin-3), the drug combination produced a synergistic cell killing 
characterized by reduced phosphorylation of VEGFR2 and Erk1/2, increased phosphorylation of 
tumor suppressor p53, and a decrease in levels of anti-apoptotic Bcl2 family members (284).     
 
The PDGFRα/β surface receptors also play an important role in angiogenesis.  Inhibition of both 
PDGFRβ and VEGFR2 in RCC resulted in enhanced suppression of tumor angiogenesis when 
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compared to inhibition of individual receptors (285).  Our laboratory has also shown that 
sorafenib-mediated inhibition of PDGFRβ plays a key role in the ability of this agent to promote 
autophagy in gastrointestinal tumor cells (286).  FLT-3 is a RTK cytokine receptor expressed on 
the surface of hematopoietic progenitor cells and is important for lymphocyte development (287).  
Mutations in FLT-3, typically internal tandem duplication (FLT3-ITD) and D835 point 
mutations, render the enzyme an onco-protein that is found in 20-30% of acute myeloid leukemia 
(AML) cases and correlates with a poor prognosis (288-289).  Lack of response to FLT3-
targetting drugs is a common occurrence in AML patients who express the FLT3-ITD and FLT3 
D835 mutations.  Interestingly, at concentrations much lower than the typical clinical dose, 
sorafenib more effectively induced cell growth arrest and apoptosis in AML cells expressing the 
FLT3-ITD and D835 mutants, than those harboring wild-type (WT) FLT3 on the order of 1000 
to 3000-fold (290). 
 
Sorafenib has entered into clinical trials for multiple forms of cancer both as a single agent and 
in combination with other approved chemotherapeutic drugs.  For example, sorafenib interacted 
with epidermal growth factor receptor (EGFR) inhibitors (erlotinib and cetuximab) in a 
pronounced synergistic fashion to reduce tumor cell migration and significantly delay tumor 
growth in NSCLC and colorectal carcinoma animal models (291).  Sorafenib in combination 
with the MEK inhibitor U0126 prevented the epithelial mesenchymal transition in hepatocellular 
carcinoma cells and reduced cellular migration as a result of downregulation of E-cadherin.  E-
cadherin is a calcium-dependent cell adhesion molecule known to play a role in tumor 
invasiveness and metastasis (292). 
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Figure 2-2:  Overview of known sorafenib targets.  Sorafenib is a promiscuous tyrosine kinase 
inhibitor developed to inhibit Raf-1, an upstream activator of the MEK/ERK pathway.  Inhibition 
of Raf-1 in theory should reduce angiogenesis, proliferation, and migration of tumor cells. 
Sorafenib was also reported to inhibit several members of the class III tyrosine kinase receptor 
family including VEGFR1, VEGFR2, VEGFR3, PDGFRβ, c-Kit, and FLT3.  When inhibited, 
pathways involved in angiogenesis, proliferation, differentiation, and metastasis are 
downregulated to promote cell death. 
 
2.3.3- Clinical relevance of Sorafenib 
Sorafenib is an orally-administered bi-aryl drug given at an optimal 400 mg b.i.d. in solid 
refractory tumors.  Sorafenib is metabolized primarily in the liver by oxidative metabolism, as 
well as glucoronidation.  Its primary metabolite found circulating in the plasma, pyridine N-
oxide, was found to be of potency comparable to that of the parent drug in vitro (293).  Sorafenib 
is approved for the treatment of two angiogenesis-driven cancers, renal and hepatic cell 
carcinoma.  Its anti-tumor activity in renal and hepatic cell cancers has been attributed to anti-
angiogenic effects caused by inhibition of specific growth factor receptor targets (254-258).  In 
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tumor cells, the activities of sorafenib have been strongly correlated with down regulation of 
anti-apoptotic Bcl-2 family member protein Mcl-1, which was the result of a translational control 
mediated via induction of ER stress. 
 
2.3.4- The aims of our studies using pemetrexed and sorafenib in combination 
Pemetrexed kills a wide variety of cancer cell types.  Hypothetically this could occur as a result 
of AMPK-induced activation of autophagy.  Activated AMPK leads to inhibition of mTOR, a 
major regulator of the autophagic response, which enables formation of the autophagosome.  
Initially, investigations were performed to determine whether pemetrexed as a single agent 
promotes a cytotoxic form of autophagy in a variety of cancer cell lines.  An autophagic response 
may occur as a result of inhibition of its secondary target (AICART) causing elevations in ZMP+ 
which result in activation of AMPK.  This response has already been established in a pemetrexed 
dose-dependent manner in NSCLC and we wished to determine if a similar response would 
occur in other tumor cell types.  Those cell models sensitive to pemetrexed were assessed to 
determine whether sorafenib could enhance pemetrexed-induced cytotoxic autophagy (Chapter 4 
Results).  Both Her2+ and triple negative breast cancer cell phenotypes were tested.  Additional 
studies were conducted to elucidate the signaling mechanisms by which these drugs interact to 
promote cytotoxic autophagy in our tumor models.  Earlier studies performed in our laboratory 
identified Src as a key mediator of cell death in HCC resultant of sorafenib-induced PDGFRβ 
down regulation. As a result, studies were performed to determine whether Src was involved in 
regulation of Erk1/2 and cell lethality in drug combination-treated breast cancer cells. In addition, 
an evaluation of the role of protein phosphatases in this response was assessed, since these 
enzymes are known to be important for regulating the Erk1/2 pathway.  Alterations seen in 
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protein phosphatase activity may indicate the validity of further investigation into the effects of 
pemetrexed/ sorafenib treatment on the de novo ceramide synthesis pathway, which has been 
shown to regulate these proteins and has been implicated in the development and progression of 
multiple cancer cell types (294).  The ultimate goal of all combination therapy studies is to pre-
clinically validate the pemetrexed/ sorafenib combination therapy in treatment of multiple tumor 
types. 
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Chapter 3: Materials and Methods 
 
 
 
3.1- Materials
3.1.1- Cell Culture:  Invitrogen reagents: RPMI 1640, DMEM, Penicillin-streptomycin, PBS, 
0.25% Trypsin-EDTA, Opti-MEM, Lipofectamine 2000. Dialyzed fetal bovine serum (Thermo 
Scientific- Hyclone dialyzed fetal bovine serum), fetal bovine serum (ThermoScientific- 
HyClone Fetal Bovine Serum), culture flasks and plates (Corning), 4-chambered glass 
microscope slides (Lab-TekII, 154526), Cryo-vials (Corning). 
 
3.1.2- Cancer cell lines: Breast- 4t1 (ATCC CRL-2539), BT474 (ATCC HTB-20), SKBR3 
(ATCC HTB-30), MCF7 (Nephew Laboratory), MCF7F (Nephew Laboratory), HCC1187 
(Nephew Laboratory), HCC1937 (Nephew Laboratory), BT549 (ATCC).  NSCLC- H460 
(Moran Laboratory).  Liver- HuH7 (Japanese Collection of Research Bioresources, JCRB-0403). 
Lymphoma- CEM (Moran Laboratory). 
 
3.1.3- siRNA:  siRNA constructs were purchased from the following venders as pre-designed 
double-stranded oligomers and resuspended in sterile water at a concentration of 20 µg/µl (20 
pmol):  si-Beclin1 (Qiagen), si-mTOR (Qiagen), si-p70 (Qiagen), si-LASS6 (Qiagen).  A set of 4 
pre-designed sequences that were functionally validated by the manufacturer, referred to as a 
FlexiTube GeneSolution, was used for each protein to be knocked down.  The siRNA construct 
details are listed in Table 1, as detailed by the manufacturers website (www.qiagen.com). 
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Table 1:  siRNA constructs.  A Qiagen FlexiTube GeneSolution, containing 4 pre-designed and 
functionally validated siRNA sequences, was used for siRNA knockdown experiments.  The 
specific sequence details for each are listed for each targeted protein as defined by the 
manufacturer. 
 
   Qiagen- FlexiTube   
  Gene ID GeneSolution catalog # FlexiTube siRNA ID
si-Beclin1 BECN1 GS8678 Hs_BECN1_3 (SI00055587) 
    Hs_BECN1_4 (SI00055594) 
    Hs_BECN1_1 (SI00055573) 
    Hs_BECN1_2 (SI00055580) 
      
si-mTOR MTOR GS2475 Hs_FRAP1_5 (SI00300244) 
    Hs_FRAP1_6 (SI02662009) 
    Hs_FRAP1_4 (SI00070462) 
    Hs_FRAP1_7 (SI03023587) 
      
si-p70α subunit RPS6KB1 GS6198 Hs_RPS6KB1_5 (SI00301721) 
    Hs_RPS6KB1_2 (SI00048594) 
    Hs_RPS6KB1_4 (SI00048608) 
    Hs_RPS6KB1_3 (SI00048601) 
      
si-LASS6 CERS6 GS253782 Hs_LASS6_5 (SI02758245) 
    Hs_LASS6_2 (SI00468335) 
    Hs_LASS6_3 (SI00468342) 
      Hs_LASS6_4 (SI00468349) 
 
3.1.4- DNA constructs:  Vector control plasmids- pEGFP-C3 parent vector (Clontech), 
pcDNA3.1 parent vector (Invitrogen), pBABE-puro Retroviral vector (Cell Biolabs).  Cloned 
plasmid constructs: pEGFP-LC3 (Spiegel Laboratory), dncaspase-9 (Vector Biolabs), Bcl-XL 
(Vector Biolabs), pcDNA3 c-FLIP-s (Wafik Eldeiry Laboratory), camTOR (Addgene), cap70 
(Addgene), caAkt (Addgene), dnAkt (Addgene), dncaspase-9 (Addgene), dnSrc (Addgene), 
dnMEK1 (Addgene), and I2PP2A (Addgene). 
 
3.1.5- DNA propogation in bacteria:  DNA propogation cell strains DH5α  and One Shot 
TOP10 (Invitrogen), Miller Luria Bertani Broth and Miller Luria Bertani broth with Agar (Difco), 
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SOC media (Invitrogen), ampicillin and kanamycin (Sigma-Aldrich), DNA plasmid purification 
kit (Qiagen), 1 Kb Plus DNA standard molecular weight marker (Invitrogen), 6X Sample 
Loading Dye (Promega), ethidium bromide (Sigma), agarose (Fisher Scientific), agarose gel 
running apparatus (Hoefer, submarine agarose gel unit). 
 
3.1.6- Chemotherapeutic drugs:  Pemetrexed/ Altima® was purchased from LC laboratories.  
Sorafenib/ Nexavar® was purchased from Sellechem (Bay-43-9006). 
 
3.1.7- Sodium dodecyl sulfate- polyacrylamide gel electrophoresis (SDS-PAGE):  The 
following items were purchased from Biorad: Running apparatus and Transfer apparatus (Mini 
PROTEAN Tetracell 1703810) and all necessary components, protein molecular weight marker 
(Dual Color Precision Plus Protein Standards– 161-0374), 40% Acrylamide/Bis-acrylamide 
(29:1) (16100146), Tween 20 (170-6531).  Fisher Scientific: 0.22µM nitrocellulose membrane 
(EP2HY00010), Immunogilin FL PVDF membrane (IPFL00010), 2-mercaptoethanol (03446I), 
20% sodium docecyl sulfate (BP1311), TEMED (BP150).  LICOR: Blocking Solution (927-
40000). 
 
3.1.8- Western blotting/ Immunohistochemistry 
The primary antibodies used in these studies were purchased from the following venders.  Cell 
Signaling: mTOR (cs2972), p-mTOR S2448 (cs2971), p70 alpha regulatory subunit (cs2041), p-
PDGFRβ Y1009 (cs3124), FGFRI (cs3472), ATG5 (cs2630), Mcl-1 (cs4572), Bcl-XL (cs2762), 
Src (cs2109), p-Src Y416 (cs2101), cleaved caspase-3 (cs9664).  Santa Cruz Biotechnologies: 
GAPDH (sc-32233), p-p70 S421/T424 (sc-7984R), LASS6 (sc-100554), Beclin1 (sc-11427), 
ERK (sc-135900), p-ERK T202/Y204 (sc-7383), Akt 1/2/3 (sc-8312R), p-Akt S473 (sc-7985R), 
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PDGFRβ (sc-339).  R&D Systems: p-p70 T389 (AF8963).  Novus Biologicals: LC3I/II (NB100-
2331) and Ki67 (NB500-170). 
 
Secondary antibodies were purchased conjugated to fluorophores for detection by fluorescence 
scanning, these include: goat α-mouse IgG- Alexa Fluor 680 (Invitrogen), goat α-rabbit IgG- 
IRDye800 (Rockland). 
 
3.1.9- Fluorescence-based techniques:  LysoTracker® Red DND-99 (Invitrogen- 7528), 
Annexin V-PI (Abcam- ab14085), Tunnel Apoptosis Detection Kit (Upstate- 17-141), H&E kit 
(Ricca Chemical Company- 3530-32) 
 
3.1.10- In vivo studies:  All animal protocols were conducted under approval of the VCU 
IACUC.  Athymic nude female mice were obtained through the Virginia Commonwealth 
University’s Division of Animal Resources.  Tumors harvested at the end point were frozen in 
Optimal Cutting Temperature Compound (Tissue-Tek 4583).  Tissue sectioning was performed 
using the Leica Cryostat.  Antibodies and fluorescent dye stains used in these studies are listed in 
previous materials sections.  Pemetrexed was reconstituted in sterile PBS (Invitrogen) and 
sorafenib was reconstituted in Cremophore EL (Sigma) 
 
3.1.11- General Supplies:  Twenty µM filter units (Nalgene), syrine and vacuum filters 
(Millipore), hemacytometer (Hausser Scientific, 0.1 mM deep) 
Chemicals: Fisher- Dimethyl sulfoxide (BP231), Tris Base (BP152), potassium chloride (BP366), 
sodium chloride (S5271), Triton X-100 (BP151), 5N sodium hydroxide solutioin (S5256), 
hydrogen chloride (AKH212), chloroform (BP1145), sodium dodecyl sulfate (BP160), N-
propanol (A451), methanol (A411), N-butanol (BP505).  Sigma Aldrich- ammonium persulfate 
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(248614), acetone (179973). American Bioanalytical- glycine (AB00730).  Pharmco-AAPER- 
200 proof ethanol (111HPLC20S).  JT Baker Chemical Company- glycerol (3-2136) 
 
Reagents:  Myriocin (Fisher), 3-methyladenine (Sigma), 0.4% Trypan Blue Dye Solution (MP 
Biomedicals), Protease Inhibitor Cocktail (Roche Applied Science), Amphotericin B (Quality 
Biologicals Inc.), bovine serum albumin (Fisher BP1600). 
 
3.1.12- Instrumentation:  LICOR Odyssey V3.0 Infrared Imager, Perkin Elmer Victor3 1420 
Multilabel Reader, Zeiss Axiovent fluorescent microscope, Accuscope light microscope, Becton 
Dickinson FACScan flow cytometer, Lipid quantification: two tandem triple quadrupole/linear 
ion trap mass spectrometers (Applied Biosystems 4000 Q TRAP and an Applied Biosystems 
3200 Q TRAP), Leica Cryostat tissue sectioner, and a Denver Instrument UB10 UltraBasic pH 
meter 
 
3.2- Methodology 
3.2.1- Cell Culture:  All breast carcinoma cell lines and H460 NCSLC cells were cultured at 37 
oC (5% (v/v CO2) in vitro using RPMI supplemented with dialyzed 5% (v/v) fetal bovine serum 
(FBS), 10% (v/v) non-essential amino acids, and 1% penicillin/ streptomycin.  HuH7 hepatoma 
cells were cultured at 37 oC (5% (v/v CO2) in vitro using DMEM supplemented with dialyzed 
5% (v/v) FBS, 10% (v/v) non-essential amino acids, and 1% penicillin/ streptomycin.  Cells 
growing in non-dialyzed fetal bovine serum containing thymidine were gradually weaned into 
dialyzed serum lacking thymidine over 2 weeks, and used for experimental analyses.  Once 
thawed, cells were used for 3 weeks before discarding. 
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3.2.2- DNA propogation in bacteria:  Plasmids (0.2 µg) were transformed into DH5α or 
TOP10 cells using the manufacturer’s protocol.  Cells were plated on LB-Agar plates containing 
the appropriate selection reagent (Ampicillin at 100 µg/mL or Kanamycin at 30 µg/mL) and 
colonies were grown overnight at 37ºC.  Individual colonies were inoculated into LB cultures 
containing the appropriate selection reagent overnight at 37ºC.  The following day, cells were 
isolated by centrifugation and plasmid DNA was isolated from each using a plasmid DNA 
purification kit as suggested by the manufacturer.  Plasmid DNA was de-salted/ further purified 
by adding 3 times the volume of 100% ethanol and 0.1 times the volume of 3M sodium acetate 
pH 5.2.  DNA was isolated by centrifugation and washed with 70% cold ethanol.  DNA pellets 
were allowed to dry at room temperature, and then resuspended in approximately 100 µL sterile 
TE Buffer supplied by the manufacturer.  DNA concentrations were determined by UV 
spectrometry at 260 nm and 280 nm wavelengths.  The 260 nm (A260) value was used in the 
following equation specific for double-stranded DNA (unknown µg/mL = 50µg/mL / 1.0 A260) 
to provide a concentration in the unit of ng/µL.  DNA stocks were diluted to 1µg/µL for use in 
DNA transfection experiments.  The 260/280 ratio was between 1.8 - 2.0 for all DNA 
preparations demonstrating acceptable DNA: protein ratios in terms of DNA purity. 
 
3.2.3- Agarose gel electrophoresis:  DNA preparations were evaluated by agarose gel 
electrophoresis to examine the quality of purified DNA. 0.8% agarose gels were prepared 
containing 0.015% ethidium bromide.  1 µg of each DNA sample was diluted in 6X DNA 
sample buffer and sterile, deionized water.  Samples, alongside a DNA standard molecular 
weight marker, were run at 100 volts for 1 hr then visualized on a ChemiDoc Molecular imager 
using the ethidium bromide filter setting.  Images were examined for levels of supercoiled DNA 
 54
versus nicked DNA as judged by the DNA standard molecular weight marker and determined to 
be of reasonable quality for transfection experiments. 
 
3.2.4- DNA transfection/ protein overexpression:  Cells were plated at 2 X 105 in 60 mm 
dishes or 2 x 104 cells per well of a 12-well plate or microscopy slide and cultured for 24 hr prior 
to transfection. Cells were transfected with 1µg/mL DNA, pertaining to the volume of media 
used for the respective dish/ well, using Lipofectamine 2000 following the manufacturer’s 
suggested protocol.  For preparation of cell lysates, cells were incubated for 48 hr after 
transfection; then treated with vehicle, individual drugs, or pemetrexed/sorafenib prior to 
harvesting whole cell lysate.  For all other assays, cells were incubated for 36 hr prior to 
treatment with drugs.  
 
3.2.5- siRNA transfection/ protein knockdown:  Cells were plated and cultured similarly to 
that for plasmid transfections. For transfection, 60 pmol of the annealed double-stranded siRNA, 
targeting our gene of interest or the negative control (a “scrambled” sequence with no significant 
homology to any known gene sequences from mouse, rat or human cell lines) was transfected 
into each 60 mm dish using Lipofectamine 2000 as per the manufacturer’s suggested protocol. 
siRNA (scrambled or experimental) was diluted in Opti-MEM at 100 pmol/ 50 µl reaction 
volume. Three µl Lipofectamine 2000 was diluted in Opti-MEM at 1 µl/ 50 µl reaction. Prior to 
introduction of siRNA, the diluted lipofectamine 2000 was allowed to equilibrate then gently 
mixed with the diluted siRNA and incubated at room temperature for 20 min to allow lipid-
siRNA complex formation.  The solution was then added dropwise to the corresponding dish and 
tilted gently to mix.  For preparation of cell lysates, cells were incubated for 48 hr after 
transfection; then treated with vehicle, individual drugs, or pemetrexed/sorafenib prior to 
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harvesting whole cell lysate.  For all other assays, cells were incubated for 36 hr prior to 
treatment with drugs. 
 
3.2.6- Validation of dialyzed fetal bovine serum:  Dialyzed serum was purchased from Thermo 
Scientific (Hyclone dialyzed fetal bovine serum, lot# ARG26916) and compared against the 
previous lot from Gemini Bioproducts (lot# A655110).  A comparison was made using CEM 
lymphoma cells grown in suspension with 5% dialyzed FBS from either the new lot or the 
previous lot.  Cells were plated in 10 cm dishes at 105 cells/ mL and the number of cells/ mL was 
determined every 2 days for 6 days by counting the number of cells per dish using a Beckman 
Coulter cell counter.  Cells were collected from each condition by centrifugation at 1000 rotation 
per minute (rpm.), and then resuspended in 1 ml Diluent II Solution.  Each cell sample was 
counted to obtain the number of cells/ mL and plotted in Sigma Plot 11.2 to obtain growth curves 
for the old lot versus the new lot of dialyzed serum to verify no significant growth changes 
between the lots of serum. 
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Figure 3-1: Validation of dialyzed fetal bovine serum in CEM lymphoma cells.  CEM cells 
were plated at 106 cells per dish in triplicate and grown for 6 days.  Every 2 days the cell 
concentration was determined for each dialyzed FBS lot using a Coulter counter machine.  We 
purchased a Thermo Scientific Hyclone dialyzed FBS lot, which we tested against the previous 
lot used for these experiments.  No significant changes in growth rates were noted between the 
two lots. 
 
3.2.7- SDS-PAGE:  Cells were plated at 5 x 105 cells / cm2 and treated with drugs at the 
indicated concentrations and after the indicated time of treatment, lysed in 2X protein sample 
buffer for whole cell lysates, then boiled for 10 min.  The boiled samples were loaded (10-100 
µg/lane, based on the gel size), alongside a protein standard molecular weight marker, onto 8-
14% SDS-PAGE gels and electrophoresis was run for 1 hr at 150 volts.  Samples were 
electrophoretically transferred onto 0.22 µm nitrocellulose or PVDF membrane for 2 hr at 250 
volts.  Membranes were blocked with LICOR Odyssey Blocking Buffer for 1 hr at room 
temperature or 4º C overnight. 
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DS-PAGE Buffer Recipes: 
5X Running Buffer
S
     10X Transfer Buffer    2x Protein Loading Buffer
               
 
L 
10 mL 
DS-PAGE gel components: 
5% Stacking gel
   30 g Tris Base        30.3 g Tris Base    1M Tris-HCl pH 6.8 
          144 g Glycine                144 g Glycine         20 mL glycerol 
        50 mL 20% SDS              50 mL 20% SDS        20 mL 20% SDS 
     deionized water to 2L                  deionized water to 1                      2 mL BME 
 Filter sterilize. Store @ 4ºC.         0.05 g bromophenol blue           deionized water to 
 
 
S
 10% Resolving gel
40% Acrylamide:Bis-acrylamide (29:1) 
L 
µL 
 water L 
esolving gel percentages were adjusted by proportionately manipulating the volumes of 
3.2.8- Western Blotting/ Immunohistochemistry:  Membranes containing blocked protein 
samples were incubated in primary antibody (0.5 – 1 µg/mL) overnight at 4ºC, washed, and then 
incubated in the corresponding secondary antibody (0.15 – 0.3 µg/mL) for 2 hr prior to analysis.  
All secondary antibodies used in these studies were conjugated to fluorophores (Alexa Fluor 680 
or IRDye 800) for examination using the LICOR Odyssey Infrared Imager.  For presentation, 
immunoblots were digitally assessed using the provided Odyssey Imager software (the data sets 
presented are the –Fold increase +/- SEM (n = 3) in expression of the indicated protein compared 
to GAPDH loading control; for phospho-proteins the –Fold increase +/- SEM (at least n = 3) is 
normalized to the total protein level of the indicated kinase or substrate). Errors are not 
numerically shown due to space restrictions in the figure panels; any indicated significant 
differences between the expression / phosphorylation levels of proteins are indicated by an 
      12.5 mL         1.25 mL 
1.5M Tris-HCl pH 8.8         12.5 mL              0 
0.5M Tris-HCl pH 6.8             0          2.5 m
10% APS            500          100 µL 
TEMED             20 µL                           10 µL 
Deionized       up to 50 mL                  up to 10 m
 
R
acrylamide and deionized water. 
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asterisk or other annotation and have a p < 0.05. Images have their color removed and were 
transferred to Powerpoint for formatting. 
 
3.2.9- Normalization of protein levels by densitometry:  All western blotting samples shown 
in the results chapters were harvested in 2X sample loading buffer containing bromophenol blue.  
Sample volumes were adjusted according to the number of cells present prior to lysis.  The 
corresponding sample volumes were subject to SDS-PAGE and examined using the LICOR 
Odyssey Infrared Imager.  Each blot was evaluated for glyceraldehydes-3-phosphate 
dehydrogenase (GAPDH) expression and the band intensity for each sample was determined 
using the LICOR Odyssey V3.0 software.  The sample band intensity for each protein of interest 
was also determined on the instrument, then expression values were calculated based on 
normalization to the determined GAPDH band densities.  The expression values given for each 
western blot are all based on values normalized to that of each sample’s GAPDH expression 
value. 
 
3.2.10- Cell Death Analysis:  For short term cell death assays and immunoblotting studies, cells 
were plated at a density of 3 x 103 per cm2 (~2 x 105 cells per well of a 12 well plate) and 24h 
after plating treated with various drugs, as indicated. In vitro pemetrexed and sorafenib 
treatments were from 1mM and 10 mM stock solutions, respectively, and the maximal 
concentration of vehicle (DMSO) in media was 0.02% (v/v).  Cells were treated with vehicle or 
pemetrexed / sorafenib for times indicated within the figure legends. For cell viability assays, 
cells were isolated at the indicated times, and either subjected to a trypan blue exclusion assay by 
counting 10 µL of each sample on a hemacytometer using the light microscope or fixed to slides 
and stained using a commercially available Diff Quick Geimsa assay kit. Alternatively, the 
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Annexin V/ propidium iodide assay was utilized to determine cell viability as per the 
manufacturer's instructions using a Becton Dickinson FACScan flow cytometer.  Samples were 
evaluated in triplicate and plotted as the average means of cell death for each sample condition 
using Sigma Plot 11.2 software.  Images were transferred to Powerpoint for formatting. 
 
3.2.11- Quantification of GFP-LC3 incorporation into early autophagic vesicles:  Cells were 
transfected with a plasmid to express an LC3-GFP fusion protein, as well as plasmids and/or 
siRNA constructs as indicated, then cultured for 36 hrs.  Cell cultures were then treated with 
drugs for the indicated times. Using the FITC filter setting on the Zeiss Axiovert 200 fluorescent 
microscope at 40X magnification, GFP-LC3+ vesicle formation was determined by counting the 
number of GFP-LC3+ vesicles present in an individual cell for a minimum of 60 unique cells per 
sample condition amongst a minimum of 10 fields of view within each sample.  These values 
were plotted in SigmaPlot 11.2, and then transferred to Powerpoint for figure formatting. 
 
3.2.12- LysoTracker Red staining for visualization of acidification of late endosomes:  Cells 
were plated in the wells of 4 chambered microscopy slides at 2 x 104 cells per well, then cultured 
for 24 hr.  Cells were either exposed to drugs or transfected with DNA and/or siRNA at 1 µg or 
20 pmol per well, respectively, using 1µl of Lipofectamine 2000 per reaction.  Cells were 
cultured in antibiotic-free media for 36 hr prior to treatment with vehicle or drugs for the 
indicated times. LysoTracker Red dye was diluted in fresh, pre-warmed 37ºC medium at a final 
concentration of 15 nM.  Culture media was aspirated from each sample, and the diluted 
LysoTracker Red stain was added to each cell sample and allowed to incubate at 37ºC for 30 min. 
Post-staining, the dye-containing media was aspirated, cell samples were gently washed 2 times 
with PBS, then finally resuspended in 250µl cold PBS per well.  Cell samples were analyzed 
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using the rhodamine filter setting on a Zeiss Axiovert 200 fluorescent microscope at 40X 
magnification using an exposure time of 3.355 seconds (brightness).   Twenty representative 
images were taken of each sample and samples were performed in triplicate.  A representative 
image for each condition and time point was selected for figure illustration generated using 
Powerpoint. 
 
3.2.13- Analysis of PP2A activity:  Cells were plated at 2 x 105 cells in 60 mM dishes in 
triplicate and cultured for 24 hr. Cells were then either treated with vehicle or drugs for 12 hrs or 
transfected with control siRNA or siRNA against LASS6 for 36 hr, and then treated with vehicle 
or drugs.  After 12 hr drug treatments, cells were washed twice with cold low phosphate lysis 
buffer to remove residual phosphatases present in the culture media, and then harvested in 500 µl 
of fresh low phosphate lysis buffer.  Samples were prepared according to the PP2A Phosphatase 
Activity Assay Kit protocol using filter-sterilized buffers prepared as described in the protocol.  
Three separate protein amounts (60 µg, 120µg, 180 µg) for each condition were 
immunoprecipitated with a monoclonal antibody against PP2A coupled to sepharose beads 
provided in the kit.  After immunoprecipitation, PP2A Antibody-couple sepharose beads were 
washed and bound protein cleaved using the manufacturer provided reagent at equal volumes for 
each sample.  The initial protein loading amounts varied slightly between each sample, however 
densitometry values obtained for the loading control were used to normalize quantified values.  
Samples were then transferred to a 96-well plate for the remainder of the protocol.  After 
incubation with the detection substrate, samples were evaluated using a Malachite Green 
protocol for determination of Absorbance at 595nm λ using a Victor 3 platereader.  Triplicate 
values obtained for each sample type, and 3 variable protein loading amounts, were averaged and 
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plotted in SigmaPlot 11.2 as fold-change in PP2A Activity relative to that of the si-control 
transfected vehicle-treated condition.  The SigmaPlot generated graph was then transferred to 
Powerpoint for figure formatting.  
 
3.2.14- Quantification of ceramide and dihydroceramide levels:  Cells were plated at 2 x 105 
cells in 60 mm dishes in duplicate every day for 3 days for a total of 6 repeats per condition and 
cultured for 24 hr prior to transfection.  Cells were transfected with siRNA against LASS6 
(Qiagen) using Lipofectamine 2000 as described above, cultured for 36 hr, then treated with 
vehicle or drug combination for 24 hr.  Cells were then harvested in 220 µl of cold PBS and 20 
µl taken for lysis and protein determination using the Bradford Assay (BioRad). Protein levels 
were normalized based on total protein levels for each sample.  Lysates were run on a denaturing 
SDS-PAGE gel to confirm normalized protein levels by evaluating the GAPDH densitometry 
values obtained using the LICOR Odyssey V3.0 software.  The remaining 200 µL cell samples 
were transferred to glass screw cap tubes containing 500 µl methanol and 250 µL chloroform 
and stored at -80ºC until all sample replicates were obtained.  A solution containing the internal 
standards was added to each cell sample.  Cell samples were sonicated and then incubated in a 
48ºC water bath with a shaker overnight (approximately 16 hr) to ensure complete digestion of 
cellular components. The following day, samples were cooled to 37ºC in a water bath and 75 µL 
of 1 M potassium hydroxide (in methanol) was added to each sample for further sonification.  
The samples were allowed to shake in a 37ºC water bath for an additional 2 hr after potassium 
hydroxide addition.  Twelve µL of glacial acetic acid was added to each sample and samples 
were sonificated again.  Lipids were harvested by centrifugation at 4000 rpm for 10 min.  The 
supernatant was transferred to a clean glass screw cap tube using a Pasteur pipette and the 
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supernatant was evaporated to dryness using a speed vacuum.  Once completely dry, the lipids 
were reconstituted in 300 µL reconstitution solvent [60:40 (60:40 methanol: deionized water): 
methanol].  Reconstituted samples were sonificated, then centrifuged at 14000 rpm for 5 min.  
200 µL of each sample was transferred to injection vials for sample analysis by mass 
spectrometry.  The peaks obtained in each sample were identified based on comparison to the 
internal standard peaks.  Data for each sample replicate (n = 6) was quantified using the 
instruments software program and plotted (p < 0.05, ± SEM) for each sample condition using 
Sigma Plot 11.2.  Data figures were transferred to Powerpoint for formatting. 
 
3.2.15- In vivo studies:  To generate an orthotopic model of breast cancer, 105 cells were 
injected into the 3rd mammary fat pad of athymic nude female mice.  Tumors were allowed to 
grow to approximately 50-100 mm3.  Mice were batched according to tumor sizes.  Animals 
were treated every day for 5 days with vehicle, pemetrexed (50 mg/kg), sorafenib (25 mg/kg), or 
a combination of the drugs.  The mice were rested for 2 days before a second round of 5 day 
treatment.  During the experiment, mouse tumors were measured every 3 days.  Mice reaching 
tumor volumes of 1700 mm3 during the experiment were humanely sacrificed.  Comparison of 
the effects of each treatment group was performed using ANOVA and the Student’s t test.  
Differences with a p-value of <0.05 were considered statistically significant.  Experiments were 
shown as a mean of multiple individual end points (± SEM).  Representative tumors from each 
group (n= 3-6 mice) were excised and frozen in optimal cutting temperature compound for 
immunohistochemial analysis.  From these mice, normal tissues (brain, kidney, lung, heart, 
spleen, liver) were also taken for analysis of toxicity in normal tissue cells by 
immunohistochemical analysis.  Cryostat sectioned tissue (10 µm sections) were fixed to slides 
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using cold acetone, rinsed with PBS, and proteins blocked on the fixed slides (10% rat sera, 1% 
bovine serum albumin, 0.1% Triton X, 0.01% Tween 20).  Tissue sections were incubated in 
primary antibody overnight at 4ºC, washed, and then incubated in secondary antibody for 2 hr at 
room temperature.  For experiments requiring a one-step dye staining procedure, tissue sections 
were fixed to the slides and incubated in the corresponding dye stain for 2 hr, then analyzed by 
fluorescence microscopy using the Axiovert Zeiss Fluorescent microscope.  Representative 
images for each treatment group were selected. 
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Chapter 4: Sorafenib enhances Pemetrexed cytotoxicity through an autophagy-dependent 
mechanism in cancer cells 
 
 
 
4.1 Pemetrexed treatment causes a dose-dependent activation of autophagy and cell death in 
multiple cancer cell types 
 
NSCLC cells were grown in media containing thymidine-less serum to mimic the growth 
conditions within a patient.  Increasing concentrations of clinically relevant doses of pemetrexed 
were given to H460 cells for various time points and autophagy was evaluated using a GFP-
tagged form of LC3 to determine the number of autophagic vesicle formed per cell in vitro.  
Incorporation of GFP-LC3 into the autophagosome can be visualized by fluorescence 
microscopy and the average number of GFP-LC3+ vesicles per cell determined.  Western blot 
analysis of cell lysates was performed after treatment of cells with vehicle or pemetrexed for 12 
hr.   
 
In drug-treated samples, western blot analysis indicated that the levels of LC3II (lipidated-LC3) 
were significantly higher than that of the vehicle-treated controls, indicating an enhancement of 
autophagic vesicle formation (Figure 4-1A). In agreement with this data, the number of GFP-
LC3+ vesicles per cell increased in a pemetrexed dose-dependent manner at 6 and 12 hr time 
points in H460 cells (Figure 4-1B).  These results demonstrated that pemetrexed was able to 
induce autophagy in H460 NSCLC cells.  To determine whether induction of autophagy was a 
protective or cytotoxic response in these cells, cell viability was evaluated using a trypan blue 
exclusion assay after 12 hr treatment with increasing concentrations of pemetrexed.  H460 cell 
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viability decreased in a pemetrexed concentration-dependent manner (Figure 4-1C).  Pre-
treatment of cells with 3-MA, a Vsp34 PI3K class III inhibitor known to inhibit induction of 
autophagy, prior to exposure with a range of pemetrexed concentrations, resulted in an increase 
in cell viability as compared to cells treated only with pemetrexed at comparable dosages (Figure 
4-1C).  Cell viability was also determined by Annexin V-PI staining for H460 cells transfected 
with control siRNA or siRNA specifically targeting the Beclin1 gene. Results from these studies 
indicated that pemetrexed treatment elicited a dose-dependent decrease in cell viability at 24 hr, 
which was significantly diminished upon knockdown of Beclin1 (Figure 4-1D). 
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Figure 4-1: Pemetrexed induces autophagy and cell death in H460 NSCLC cells that are 
suppressed by treatment with 3-MA or knockdown of Beclin1.  Cells were cultured in 
dialyzed media not containing exogenous thymidine, then treated vehicle (PBS) or pemetrexed 
for the indicated times.  (A) 6 hr and (B) 12 hr treatment of H460 cells with pemetrexed causes 
an increase in LC3II protein levels as judged by western blot analysis.  H460 cells were 
transfected with a plasmid to express control GFP or GFP-LC3, then treated with vehicle or 
increasing concentrations of pemetrexed for the indicated times.  The number of GFP-LC3+ 
vesicles per cell at 6 and 12 hr time points was analyzed using fluorescence microscopy (*p<0.05 
greater than vehicle control). (C) 3-MA (5mM, 30 min prior to drug treatment) protects H460 
cells from the cytotoxic effects of pemetrexed at 24hr drug treatment.  Cell viability was 
determined by Annexin V-PI staining. (# p<0.05 greater than corresponding value in vehicle 
treated cells) (D) Knockdown of Beclin1 protects H460 cells from the cytotoxic effects of 
pemetrexed at 24 hr drug treatment. Cell viability was determined by Annexin V-PI staining (# 
p<0.05 greater than corresponding value in vehicle treated cells).  
 
 
Studies were performed to determine whether pemetrexed treatment causes a similar dose 
response relationship in other tumor cell types.  In spontaneous mouse mammary (4T1), human 
mammary (BT474), and human hepatic (HuH7) carcinoma cell lines pemetrexed treatment was 
shown to induce a dose-dependent increase in autophagic vesicle formation as judged by the 
number of GFP-LC3+ vesicles per cell (Figure 4-2A-C). 
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Figure 4-2: Treatment with pemetrexed causes an increase in autophagic vesicle formation 
in mammary and hepatic carcinoma cells.  Cells were plated in dialyzed media, transfected 
with GFP-LC3 expressing plasmid, then cultured for 36 hr prior to drug treatment.  Cells were 
treated with vehicle (PBS) or varying concentrations of pemetrexed for 12 hr, then analyzed for 
GFP-LC3+ vesicle formation by fluorescence microscopy.  Samples were performed in triplicate 
and 40 random cells selected from each sample for determining the average number of 
autophagic vesicles per cell.  (A) Pemetrexed causes a dose-dependent increase in autophagic 
vesicle formation at 12 hr in 4T1 murine breast carcinoma cells (*p<0.05 greater than vehicle 
control) and (B) BT474 mammalian breast carcinoma cells.  (C) Pemetrexed causes an increase 
in autophagic vesicle formation at 6 hr and a dose-dependent response at 12 hr drug treatment in 
HuH7 hepatic carcinoma cells. 
 
 
Knockdown of Beclin1 or pre-treatment with 3-MA in these cell lines resulted in a significant 
reduction in the cytotoxic effects of the pemetrexed, even in cells treated with the highest dose of 
pemetrexed used in these studies. (Figure 4-3).  These findings were comparable to that of H460 
NSCLC cells, suggesting that these tumor types also rely on an autophagy-dependent mechanism 
for pemetrexed-induced cell death.  Data for other tumor cell types (glioblastoma, pancreatic and 
bladder carcinomas) treated with similar concentrations of pemetrexed also demonstrated a dose-
dependent reduction in cell viability (data not shown). 
 
PTX (µM) PTX (µM) PTX (µM)
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Figure 4-3: Pemetrexed lethality is autophagy-dependent in multiple tumor types. Cells 
were plated in media containing dialyzed serum and transfected with control siRNA or siRNA 
targeting Beclin1, then cultured for 36 hr prior to drug treatment.  Cell samples were treated with 
PTX (3µM) for 24 hr then evaluated for cell viability by Annexin V-PI staining. Treatment with 
pemetrexed resulted in a decrease in cell viability; which is prevented (* p < 0.05) by 
knockdown of Beclin1 or treatment with 3-MA in 4T1, BT474, and HUH7 cells. 
 
 
4.2 Sorafenib interacts with pemetrexed to enhance pemetrexed toxicity and induce autophagy in 
multiple tumor types 
 
Sorafenib, a multi-kinase inhibitor of class III RTKs (PDGFRβ, VEGFRs, cKit, FLT3), has been 
shown to promote both cytoprotective and cytotoxic forms of autophagy in several tumor cell 
types (295-297).  In H460 NSCLC cells, varying concentrations of pemetrexed and sorafenib 
interacted in a greater than additive fashion to enhance cell death (Figure 4-4).  This response 
was noted using concentrations of pemetrexed and sorafenib below each drugs clinically relevant 
dose. 
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Figure 4-4:  Co-treatment with pemetrexed and sorafenib enhanced toxicity in H460 
NSCLC cells.  Cells were cultured in media containing thymidine-less serum and treated with 
vehicles (PBS and DMSO), individual drugs, or a combination of pemetrexed and sorafenib for 
24 hr.  Samples were performed in triplicate and cell death evaluated using a trypan blue 
exclusion assay.  A greater than additive enhancement in cell death was demonstrated for values 
having a *p<0.05 greater than vehicle control. 
 
To determine the effectiveness of pemetrexed/sorafenib toxicity in multiple cancer cell types, 
breast and hepatic carcinoma cell lines were subject to the same treatment conditions used above.  
Cell death was evaluated in these cell types using a trypan blue exclusion assay for samples 
treated with vehicle, individual drugs, or a combination of the two at the lowest effective 
concentrations of each used to generate the previous data figure.  A greater than additive 
enhancement of cell death was noted in 4T1, H460, BT474, and HuH7 cells when exposed to 
combination therapy in comparison to vehicle or individual drug controls (Figure 4-5A-D).  
Knockdown of Beclin1 was shown to suppress the cytotoxic interaction of pemetrexed/sorafenib 
in these cells (Figure 4-5A-D).  
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Figure 4.5- Pemetrexed interacts with sorafenib to enhance cell death that is suppressed by 
knockdown of Beclin1 in multiple tumor types.  Cells were cultured in media containing 
thymidine-less serum, transfected with control siRNA or siRNA targeting Beclin1, then cultured 
for an additional 36 hr.  Cells were then treated with vehicles (PBS and DMSO), individual drugs, 
or a combination of pemetrexed (µM) and sorafenib (µM) for 24 hr.  Co-treatment of cells with 
pemetrexed and sorafenib for 24 hr causes a greater than additive increase in cell death for all 
tumor cell types* (p<0.05 greater than vehicle control), as compared to vehicle or individual 
drug controls; however knockdown of Beclin1 suppresses this effect** (p<0.05 less than 
corresponding value in siSCR cells) in (A) 4t1, (B) H460, and (C) BT474, and (D) HUH7 cells. 
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Autophagy was measured in breast and hepatic carcinoma cell lines co-treated with pemetrexed 
and sorafenib using the GFP-LC3+ vesicle formation assay, as described previously.  Results 
indicated that HuH7, BT474, and 4T1 cells demonstrated a significant increase in autophagic 
vesicle formation for the drug combination treatment, compared to vehicle or individual drug-
treatment controls (Figure 4-6A-C).  Down-regulation of Beclin1 in these cells was shown to 
block this effect for each cell type (Figure 4-6A-C).  These results suggest that pemetrexed and 
sorafenib cytotoxicity relies upon an autophagic dependent mechanism. 
 
 
 
 
Figure 4-6: Pemetrexed interacts with sorafenib to enhance autophagy that is suppressed 
by knockdown of Beclin1 in multiple tumor types.  Cells were cultured in media containing 
thymidine-less serum, transfected with a plasmid expressing GFP-LC3 and control siRNA or 
siRNA targeting Beclin1, then cultured for 36 hr prior to drug addition.  Cells were treated with 
vehicles (PBS and DMSO), individual drugs (µM), or a combination of the drugs for 12 hr prior 
to analysis of GFP-LC3+ vesicle formation by fluorescence microscopy.  Samples were 
performed in triplicate and 40 random cells selected for evaluation of each sample.  Combination 
treatment caused a significant increase in the number of GFP-LC3+ vesicles per cell* (p<0.05 
greater than vehicle), when compared to vehicle and single drug treatment controls.  This effect 
is blocked by knockdown of Beclin1** in these cells (p<0.05 less than corresponding value in 
siSCR-transfected cells. 
 
 
4.3 Pemetrexed/ sorafenib combination therapy is an effective therapeutic for triple negative 
breast cancer 
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Development of estrogen independence as a result of exposure to estrogen receptor inhibitors in 
ER+ breast cancers is one of the most prevalent types of acquired drug resistance in cancer 
therapy.  For this reason, development of novel chemotherapeutic strategies for treatment of 
estrogen-independent breast cancer is important and necessary.  As a result, studies were 
performed to assess the effectiveness of pemetrexed/sorafenib combination therapy in the 
treatment of Her2+ and triple-negative breast cancer cells, wherein the cell no longer responds to 
estrogen.  Cell death was evaluated following drug combination treatment of BT549 (triple 
negative), SKBR3 (Her2+), HCC1187 (triple negative), and HCC1937 (triple negative) cells.  
Results indicated that individually, sorafenib and pemetrexed were able to induce a dose-
dependent increase in cell death in all cell lines tested. In addition, the drug combination was 
able to induce a greater than additive enhancement of cell killing (Figure 4-7A-D). 
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Figure 4-7:  Pemetrexed and sorafenib interact in a dose-dependent manner to cause cell 
death in Her2+ and triple negative breast cancer cells.  Cells were plated in media containing 
dialyzed serum for 24 hr prior to drug treatment.  Co-treatment with pemetrexed (µM) and 
sorafenib (µM) for 24 hr resulted in a significant increase in cell death* (p<0.05 greater than 
vehicle) as compared to vehicle or individual drug-treatments in (A) HCC1187, (B) SKBR3, (C) 
HCC1937, and (D) BT549 cells, as judged by trypan blue exclusion. 
 
 
Faslodex (Fulvestrant) has proven beneficial for the treatment of ER+ metastatic breast cancer 
cells in post-menopausal patients previously treated with, but now resistant to tamoxifen.  This 
effect is likely due to the distinct mode of action by which fulvestrant inhibits estrogen signaling 
(298-299).  Fulvestrant is typically issued as a second-line therapy to breast cancer patients 
having developed a resistance to a first-line chemotherapeutic regimen, while there are many 
patients that will also develop a resistance to fulvestrant (299-300).  MCF7 is a well-
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characterized ER+ mammary ductal epithelial cell line isolated from a pleural effusion of a post-
menopausal woman (301).  Nephew and colleagues developed a fulvestrant-resistant MCF7 
model (MCF7F) through stringent selection of cells able to bypass estrogen-dependence after 
exposure to fulvestrant at high dosage for an extended period of time (302).  Studies were 
performed to examine whether the pemetrexed/sorafenib combination would be equally as toxic 
for fulvestrant-resistant and non-resistant breast cancer cells.  Both parental MCF7 and 
fulvestrant-resistant MCF7 (MCF7F) cells demonstrated a dose-dependent increase in cell death 
for individual drug treatments.  When analyzing drug combination lethality, both cell lines 
responded in at least an additive fashion, compared to that of the individual drugs; however 
MCF7F cells were more sensitive to the drug combination treatment (Figure 4-8).   
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Figure 4-8:  Co-treatment with pemetrexed and sorafenib cause a dose-dependent increase 
in cell death in parental and Fulvestrant-resistant MCF7 cells.  Cells were plated in media 
containing thymidine-less serum for 24 hr prior to drug treatment.  Cells were treated with 
vehicles (PBS and DMSO), individual drugs (µM), or drug combinations of increasing dosages 
for 24 hr.  Cell death was analyzed by trypan blue exclusion.  Treatment with pemetrexed and 
sorafenib resulted in as dose-dependent enhancement in cellular toxicity for single drug 
treatment conditions, as well as illustrated a greater than additive enhancement of cell killing in 
(A) parental, estrogen-dependent MCF7¶ (p<0.05 greater than vehicle control) and (B) 
Fulvestrant-resistant MCF7-F¶¶ (p<0.05 greater than vehicle control) cells. 
 
 
4.4 MCF7F cells express higher levels of autophagy-related proteins and are more sensitive to 
pemetrexed/ sorafenib treatment than their estrogen-dependent counterparts  
 
Data in this dissertation has indicated that the autophagic cellular machinery is important for 
sorafenib/pemetrexed induced toxicity in multiple tumor cell types.  The expression levels of the 
proteins involved in autophagy were assessed to further validate these findings.  Western blot 
analysis of several of the key proteins involved in the regulation of autophagy was determined 
for parental and fulvestrant-resistant MCF7 cells after treatment with vehicle, individual drugs, 
or the pemetrexed/ sorafenib combination (Figure 4-9).  In both MCF7 and MCF7F cells, 
treatment with pemetrexed/ sorafenib caused an increase in the levels of LC3II (the lipidated 
form of LC3 necessary for autophagosomal membrane formation) and decreased levels of p62 (a 
marker for autolysosome activity when reduced).  Clinical studies evaluating patient tumor 
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samples have implicated the loss of Beclin1 in the process of tumor formation of breast and lung 
carcinoma (303-304).  These studies suggested that autophagy exists as a protective mechanism 
in these cells.  Interestingly, MCF7 cells are documented as a haplotype for expression of the 
Beclin1 gene (307-308).  MCF7F cells express significantly higher basal levels of Beclin1 and 
the ATG5-12 complex than the parental strain. However, Beclin1 and ATG5-12 levels increased 
significantly for parental MCF7 cells when co-treated with pemetrexed and sorafenib, while 
there was no significant change in levels of these proteins for combination drug-treated MCF7F 
cells.  The protein expression of anti-apoptotic Mcl-1 was reduced for both cell strains when 
treated with sorafenib and further reduced with combination treatment in MCF7F cells.  The 
expression of Bcl-XL was reduced for MCF7F cells when treated with individual drugs or the 
combination (Figure 4-9). 
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Figure 4-9:  Fulvestrant-resistant MCF7F cells express higher basal levels of autophagy 
related proteins than do their estrogen-dependent counterparts.  Cells were plated in media 
containing thymidine-less serum for 24 hr prior to drug treatment.  Cells were treated with 
vehicle, individual drugs, or a combination of pemetrexed and sorafenib for 24 hr.  The levels of 
autophagy-related proteins were evaluated for each condition by western blot analysis.  The 
expression values provided for each condition were calculated based on their respective GAPDH 
densitometry values.  MCF7F expressed higher basal levels of Beclin1, ATG5-12, LC3II, p62, 
Mcl-1, and Bcl-XL.  Pemetrexed/ sorafenib combination treatment caused a significant increase 
in the levels of Beclin1, ATG5, and LC3II (lapidated-LC3I) in both parental and fulvestrant-
resistant MCF7 cells.  P62 levels were significantly reduced in combination treated cell samples, 
as compared to vehicle or individual drug samples. 
 
 
Pemetrexed and sorafenib co-therapy leads to an induction of autophagy, as well as an 
enhancement in cell death for multiple tumor types.  Judging by alterations in the expression 
levels of autophagy-related proteins in cells treated with both drugs compared to controls, one 
would expect the mechanism of cell death to be one that could involve the intrinsic portion of the 
apoptotic pathway which utilizes the mitochondria.  To examine this, the amount of cell death in 
cells over-expressing a dominant-negative form of caspase-9 (dncaspase-9) was evaluated.  
Over-expression of a non-functional form of caspase-9 caused a minor decrease in pemetrexed/ 
sorafenib lethality in MCF7, while causing a moderate decrease in combination-treated MCF7F 
cells.  These results suggest that the intrinsic apoptotic pathway may have a role in drug 
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combination lethality (Figure 4-10A-B).  Overexpression of the anti-apoptotic Bcl-XL led to 
reduction in cell death in both cell lines.  Overexpression of c-FLIP-s (an inhibitory protein of 
caspase-8 within the extrinsic pathway) caused no significant change in drug combination 
induced cytotoxicity in MCF7 or MCF7F cells (Figure 4-10A-B). 
 
 
 
BA 
 
 
Figure 4-10:  Toxicity resultant of combination treatment with pemetrexed and sorafenib 
follows an intrinsic, rather than extrinsic, death signaling mechanism.  Cells were plated in 
media containing dialyzed serum and cultured for 24. Cell samples were infected with a vector 
control plasmid or a plasmid expressing the gene of interest for 36 hrs prior to drug treatment.  
Overexpression of a dominant negative form of caspase 9 or Bcl-XL decreases drug combination 
lethality in (A) MCF7 and (B) MCF7F cells, however overexpression of c-FLIPs has no effect on 
combination drug induced death* (p<0.05 less than CMV vector control-transfected cells). 
 
 
Phosphorylation levels of the major signal transduction pathway proteins within these cells were 
examined, in an attempt to further define the mechanisms by which pemetrexed/sorafenib 
treatment propagates a cytotoxic cell death signal.   MCF7F cells contain higher basal levels of 
PDGFRβ and FGFR, known sorafenib targets, than the parental strain (Figure 4-11A).  Based on 
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this observation, analysis of the phosphorylation levels of signaling proteins involved in 
propagation of these growth factor-induced responses were assessed.  Combination therapy more 
significantly enhanced downregulation of phospho-mTOR S2448 in MCF7 and MCF7F cells, 
than did either of the individual drugs alone (Figure 4-11A).  Phospho-Erk1/2 levels were 
significantly enhanced in drug combination samples for parental MCF7 cells.  MCF7F cells 
demonstrated an increase in ERK1/2 phosphorylation, while the effect was not as dramatic as 
that for parental MCF7 cells.  Thus, even in the presence of sorafenib, Erk1/2 was activated in 
this system.  Treatment with pemetrexed or sorafenib as single agents modestly inhibited the 
levels of phospho-p70 T421/S424 and phopho-p70 T389 in parental MCF7 and estrogen-
independent MCF7F cells (Figure 4-11A).  MCF7F cells were found to express higher basal 
levels of phospho-ERK1/2, p70, and mTOR than the parental MCF7 strain (Figure 4-11B).                  
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Figure 4-11:  Pemetrexed/ sorafenib co-treatment alters signaling through mTOR and 
MAPK pathways.  Cells were plated in media containing thymidine-less serum for 24 hr prior 
to treatment.  Cells were treated with vehicles (PBS and DMSO), individual drugs, or a 
combination of pemetrexed and sorafenib for 24 hr.  Lysates were harvested and denaturing gels 
run to determine phospho-protein levels.  (A) Combination treatment with pemetrexed and 
sorafenib downregulates mTOR* and p70* activation (p<0.05), while strongly activating the 
Erk1/2# signaling pathway (p<0.05).  Basal levels@ of p-p70 S6 kinase T389 and T421/S424, p-
mTOR S2448, and total PDGFRß were higher in Fulvestrant-resistant MCF7 cells, as compared 
to their estrogen-dependent counterparts (p<0.05).  (B) Quantification of protein levels were 
plotted illustrating the basal levels of the indicated phospho-proteins for BT474, MCF7, and 
MCF7F cells.  MCF7F cells have higher basal activity for ERK1/2, p70, and mTOR. 
 
 
The importance of the signaling proteins implicated in the western blot findings was determined.  
Initially, the levels of PDGFRβ were manipulated in MCF7 and MCF7F cells.  Knockdown of 
PDGFRβ could potentially mimic the effects of sorafenib treatment if the drug was preferential 
for this receptor using this particular dose range.  Western blot analysis confirmed the reduction 
in PDGFRβ levels by siRNA in both cell lines (Figure 4-12A).  Results indicated that 
knockdown of PDGFRβ led to an enhanced cell death, in a pemetrexed mediated dose-dependent 
manner in MCF7 and MCF7F cells, this effect was more pronounced in MCF7F (Figure 4-12B).            
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Figure 4-12:  MCF7F cells are more sensitive to pemetrexed treatment than the estrogen-
dependent parental strain and pemetrexed-induced toxicity can be enhanced by 
knockdown of PDGFRβ.  Cells were plated in media containing dialyzed serum and cultured 
for 24 hr prior to transfection with control siRNA or a siRNA targeting PDGFRβ.  36 hr post 
transfection, cells were treated with pemetrexed at the indicated dosages.  24 hr after treatment 
cells either (A) harvested for lysate to demonstrate knockdown of PDGFRβ or subject to a (B) 
trypan blue exclusion assay to determine cell death percentages.  Both parental and Fulvestrant-
resistant MCF7 cells became more sensitive to pemetrexed treatment upon knockdown of 
PDGFRβ¶ (p<0.05). 
 
 
The importance of mTOR and p70 S6K in the interactions of pemetrexed and sorafenib was 
determined, by transiently knocking down expression of these proteins.  Western blot analysis of 
mTOR and p70 verified a reduction in the levels of these proteins by siRNA methods (Figure 4-
13A).  Simultaneous knockdown of p70 and mTOR was shown to enhance drug combination 
lethality in both cell lines; however the effect of knocking down both of these proteins 
simultaneously must be considered when evaluating these findings.  Comparatively speaking, 
MCF7F cells appeared to be more sensitive to combination treatment following knockdown for 
mTOR and p70 (Figure 4-13B-C).  Knockdown of mTOR and p70 may have sensitized MCF7F 
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to pemetrexed-only treatment; while taking into consideration the consequent effects of 
knockdown of these proteins in cells (Figure 4-13C).  Downregulation of either protein alone did 
not appear to promote combination drug toxicity (data not shown). 
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Figure 4-13:  mTOR and p70 S6 kinase pathways play an important role in pemetrexed/ 
sorafenib lethality.  Cells were plated in media containing thymidine-less serum 24 hr prior to 
transfection with control siRNA or siRNA targeting mTOR and p70, simultaneously.  
Transfected cells were cultured for 36 hr prior to treatment with vehicle, individual drugs, or a 
combination of pemetrexed and sorafenib for 24 hr.  (A) The levels of mTOR and p70 were 
determined by western blot analysis to verify knockdown of the genes.  (B) Knockdown of 
mTOR and p70 sensitize MCF7¶ and MCF7F¶ cells to combination treatment, as judged by 
trypan blue exclusion (p<0.05 greater than vehicle). 
 
 
Using a separate approach, constitutively active forms of mTOR and p70 were overexpressed in 
MCF7 and MCF7F cells and these cells were then subjected to the same analysis.  Results from 
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these studies demonstrated that overexpression of constitutively active forms of either protein led 
to reductions in pemetrexed toxicity in parental MCF7 cells, while combination treatment further 
enhanced a reduction in cell death in these cells (Figure 4-14A-B).  These results may be 
suggestive of lower levels of TS expression in the parental cell line because sensitivity of 
MCF7F cells to pemetrexed as a single agent was enhanced.  Similar to the siRNA knockdown 
data for these proteins, when constitutively active forms of both mTOR and p70 were co-
expressed, there was a more pronounced effect than either individually.  Overexpression of 
constitutively active forms of mTOR and p70 caused a more pronounced reduction in cell death 
for MCF7F cells than MCF7 (Figure 4-14B). 
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Figure 4-14:  Constitutive activation of mTOR and p70 S6 kinase pathways desensitizes 
MCF7 cells to pemetrexed/ sorafenib cotherapy.  Cells were plated in media containing 
thymidine-less serum and cultured for 24 hr prior to transfection.  Cells were transfected with 
vector control plasmid or plasmids to express constitutively active forms of mTOR (ca-mTOR), 
p70 (ca-p70), or both.  Cells were treated with vehicle, individual drugs, or a combination of 
pemetrexed and sorafenib for 24 hr prior to determination of cell death using a trypan blue 
exclusion assay.  Overexpression of constitutively active mTOR or constitutively active p70 
caused a reduction* in toxicity for combination drug treatments (p<0.05 less than corresponding 
value in CMV vector-transfected cells) in (A) MCF7 and (B) MCF7F cells, as compared to 
vector control cells.  Overexpression of constitutively active mTOR and constitutively active p70 
in combination further reduced# cell death in both cell lines below that of individual 
manipulations (p<0.05). 
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4.5 Pemetrexed and sorafenib interact to promote cell death in vivo 
 
The ultimate goal of this study is to have pemetrexed/sorafenib co-therapy translated into the 
clinical setting.  In order to examine the effectiveness of this drug combination in an in vivo 
tumor environment, these drugs were tested in an orthotopic BT474 mammary carcinoma mouse 
model.  Pemetrexed/sorafenib co-treatment significantly reduced tumor growth in mice, when 
compared to vehicle and individual drug treatment (Figure 4-15A).  Immunohistochemistry was 
performed on tissue slices from mice under different treatment conditions to evaluate the levels 
of cell proliferation and apoptosis.  Tumor growth data correlated with immunohistochemistry 
data (Figure 4-15B).  A decrease in Ki-67 staining (for proliferation), demonstrated a reduction 
in proliferation for combination drug-treated cells.  In addition, apoptosis was enhanced for 
pemetrexed/ sorafenib-treated tumors, which correlated with tumor growth data. 
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Figure 4-15:  Pemetrexed and sorafenib interact to reduce tumor growth in a breast 
cancer-induced mouse model.  Cells were injected into the 4th mammary fat pad of athymic 
nude mice and allowed to form tumors (~75mm3), then batched according to tumor size.  
Animals were treated with vehicles (PBS or chromophore), individual drugs, or a combination of 
pemetrexed (50 mg/kg) and sorafenib (25 mg/kg) once a day for 2 rounds of 5-day treatment, 
separated by 2 days.  Tumor sizes were recorded every 3 days during the course of the 
experiment.  Mean tumor volumes were plotted per group.  (A) Combination treatment with 
pemetrexed/ sorafenib resulted in a significant growth reduction for BT474 cells, as compared to 
vehicle and individual drug treatments* (p<0.05).  (B)  Tumor tissue slices were harvested 14 
days after the last drug treatment and immunohistochemistry preformed to evaluate the levels of 
apoptosis and cell proliferation, as well as cell morphology in comparison to healthy tissue 
controls.  All in vivo studies were conducted by Dr. Hossein Hamed. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 86
 
 
 
 
 
Chapter 5: Results- Sorafenib and pemetrexed toxicity in cancer cells is mediated via Src-
Erk signaling 
 
 
 
The studies in this chapter sought to understand in greater detail how the anti-folate pemetrexed 
and the multi-kinase inhibitor sorafenib interact to kill mammary carcinoma cells.  A previous 
study combining pemetrexed and sorafenib in prostate cancer cells demonstrated a pronounced 
activation of Erk1/2 in response to combination treatment (295).  This chapter addresses the 
involvement of MEK1/2-Erk1/2, Src, the tumor suppressor PP2A, the inhibitor 2 of protein 
phosphatase 2A (I2PP2A/ SET), and the de novo ceramide synthetic machinery in drug 
combination-induced cell killing.
 
5.1 Pemetrexed induces a cytotoxic form of autophagy in Her2+ and triple negative breast 
cancer cells 
 
In Her2+ BT474 cells, pemetrexed/ sorafenib combination drug therapy was shown to cause a 
significant Beclin 1-dependent increase in early autophagic vesicle formation, as judged by GFP-
LC3+ autophagic punctae formation (Figures 5-1A and 5-1B).  Treatment of BT474 and MCF7F 
cells with pemetrexed and sorafenib resulted in a pronounced increase in cell death, while this 
effect was significantly attenuated by knockdown of Beclin1 (Figure 5-1C). 
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Figure 5-1:  Pemetrexed-induced autophagy and tumor cell killing is suppressed by 
knockdown of Beclin1.  Cells were plated in media containing dialyzed serum and cultured for 
24 hr prior to transfection GFP-LC3 and control siRNA or siRNA targeting Beclin1, as well as 
the GFP-LC3 expression plasmid.  Cells were treated with vehicle or pemetrexed/ sorafenib 
combination prior to analysis of autophagasome formation.  (A) Western blot analysis for 
verification of Beclin1 knockdown.  (B) Autophagosomal lysosome formation was quantified by 
determination of GFP-LC3+ vesicles per cell after 24 hr exposure to vehicle or combination drug 
treatment.  Pemetrexed/ sorafenib treatment caused a significant increase in autophagic vesicle 
formation in BT474 cells, which was attenuated upon knockdown of Beclin1# (p<0.05 less than 
corresponding value in siSCR cells). (C) Pemetrexed/ sorafenib cotreatment for 24 hr caused an 
increase in cell death for BT474 and MCF7F cells, which was reduced upon knockdown of 
Beclin1# (p<0.05 less than corresponding value in siSCR cells). 
 
 
These breast cancer cell models were further examined for progression of early autophagic 
vesicles to late stage endosomes when treated with the drug combination using Lysotracker Red 
staining, which is sensitive for late stage endosome acidification.  The presence and intensity of 
red staining is indicative of the levels of proteosomal degradation occurring in these vesicles 
(305).  Treatment of BT474 and MCF7F cells demonstrated a time-dependent increase in late 
stage endosomal acidification (Figure 5-2A).  The most prominent increase in endosomal activity 
was seen at 24 hr.  Knockdown of Beclin1 suppressed this effect in both BT474 and MCF7F 
cells (Figure 5-2B-C). 
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compartment; thus preventing LC3 degradation in autophagolysosomes (307-308).  Results 
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Figure 5-2:  Pemetrexed interacts with sorafenib in a time-dependent fashion to increase 
autophagy which is suppressed by knockdown of Beclin1.  Cells were plated in media 
containing dialyzed serum and cultured for 24 hr prior to drug treatment for variable times or 
transfection with control siRNA or siRNA targeting Beclin1.  For non-transfected cell samples, 
cells were treated with vehicle or a combination of pemetrexed and sorafenib various time points 
than evaluated for (A) lysosomal protein degradation at various time points.  For transfected 
samples, 36 hr post-transfection with si-Beclin1, cells were treated with vehicle or a combination 
of pemetrexed and sorafenib for 6 or 24 hr time points, then evaluated for lysosomal protein 
degradation in (B) MCF7F and (C) BT474 cells.  Both cell lines demonstrated an increase in 
acidic lysosome formation upon treatment with pemetrexed and sorafenib at various time points, 
compared to vehicle-treated cells; while knockdown of Beclin1 reduced this effect. 
 
 
5.2 Pemetrexed/ sorafenib toxicity is dependent upon the generation of ROS 
 
In many cases, chemotherapeutic drug toxicity is preceded by the generation of ROS, which may 
promote oxidative stress in cells.  Increased levels of ROS can result in oxidation of lipids, 
proteins, and DNA, ultimately leading to cell death (306).  Due to their highly reactive nature, 
ROS disrupt the integrity of the lysosomes causing lysosomal membrane permeabilization and 
the release of molecules that trigger autophagy and caspase-induced cell death.  To further 
validate the importance of late stage endosome formation for pemetrexed/ sorafenib-induced 
cellular toxicity in the cell models used in this study, we pre-treated cells with ammonium 
chloride (NH4Cl), an agent known to inhibit endosomal acidification by neutralization of this 
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igure 5-3:  Inhibition of autophagy at the mitochondrial level abolishes drug combination-
duced cell death.  Cells were plated in dialyzed serum-containing media and cultured for 24 hr 
.3 Pemetrexed/ Sorafenib cytotoxicity is regulated by Src 
iminary experiments to be a possible 
c-Src.  Earlier studies in our laboratory reported that sorafenib treatment can lead to inhibition of 
indicated a significant reduction in drug combination-induced cell toxicity in BT474 and MCF7F 
cells pre-treated with NH4Cl (Figure 5-3A-B).  This data further confirms the importance of 
lysosomal function for promoting pemetrexed/ sorafenib toxicity in breast cancer cells. 
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prior to vehicle or pemetrexed/ sorafenib treatment +/- NH4Cl.  Cells were evaluated for viability 
using a trypan blue exclusion assay.  Treatment with NH4Cl resulted in an abolishment of 
pemetrexed/ sorafenib induced drug lethality, as compared to vehicle treated cells for both 
BT474 and MCF7F cells. 
 
 
5
 
PDGFRβ, a known sorafenib target, was identified in prel
factor in the pemetrexed/ sorafenib co-therapy response.  PDGFRβ was shown to be expressed at 
higher levels in fulvestrant-resistant MCF7 cells, compared to parent MCF7 cells (illustrated in 
the Chapter 4).  MCF7F tumor cells are more aggressive in terms of tumorigenicity, while they 
demonstrate a greater sensitivity to drug combination treatment than the estrogen-dependent 
parental strain.  To further define the mechanisms contributing to apoptosis following drug-
induced reductions in PDGFRβ, we examined one of its prominent downstream effector kinases, 
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We examined a possible role for Src in the Erk1/2-mediated response of tumor cells to 
pemetrexed/ sorafenib co-therapy.  Knockdown of PDGFRβ in BT474 cells was accompanied by 
PDGFRβ and activation of Src through a CD95-dependent mechanism (256-257,286).  
Upregulation of Src has been strongly correlated with invasion and cell motility, which are 
characteristic of tumor cell progression (309).  Src becomes activated by PDGFRβ at the plasma 
membrane, an event which is mediated through its interactions with phosphorylated Tyr579 and 
Tyr581 residues of PDGFRβ (310).  Src can transmit its signal to a number of downstream 
targets including MEK/Erk and Akt.  In the first chapter of results, Erk1/2 was shown to be 
activated in response to pemetrexed/ sorafenib treatment in parental and estrogen-independent 
breast cancer cells.  The MEK/Erk and Akt pathways communicate with one another on multiple 
levels to regulate Src signaling.  For this reason, the mechanisms by which Src mediates its 
biological effects are not always clear. 
 
an approximate 2-fold increase in phospho-Src Y416 levels (Figure 5-4A, left).  Overexpression 
of a dominant negative form of Src (dnSrc) was verified by western blot (Figure 5-4A, right).  
Overexpression of dnSrc suppressed drug-induced autophagic vesicle formation in BT474 cells 
(Figure 5-4B).  MCF7F cells demonstrated a reduced percentage of drug combination-induced 
cell death when overexpressing dnSrc, as compared to vector-transfected cells (Figure 5-4C). 
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Figure 5-4:  Src is an important player in the mechanistic means by which pemetrexed and 
sorafenib enhance cell death.  Cells were plated in dialyzed serum- containing media then 
cultured for 24 hr prior to transfection with vector control plasmid or a dnSRC-expressing 
construct.  36hr post-transfection, cells were treated with vehicle or a combination of pemetrexed 
and sorafenib for the indicated times, then evaluated for GFP-LC3 vesicle formation or cell 
lethality.  (A) Western blot analysis of p-Src Tyr416 (left) in BT474 cells when PDGFRβ is 
downregulated by treatment with sorafenib, as well as western blot analysis to verify 
overexpression of dominant-negative Src.  (B) Overexpression of dominant-negative Src 
attenuates drug combination-induced autophagic vesicle formation in BT474 cells# (p<0.05 less 
than corresponding value in CMV vector control-transfected cells) and (C) reduces cell toxicity 
in MCF7F cells, as compared to the vector control-transfected cotreatment samples# (p<0.05 less 
than corresponding value in CMV vector control-transfected cells). 
 
 
5.4 Pemetrexed/ sorafenib toxicity is mediated by the MEK/Erk pathway 
 
A pronounced increase in phospho-Src Y416 levels upon co-treatment of breast cancer cells with 
pemetrexed and sorafenib led us to the question of which downstream effector pathways are 
being activated by Src during this response.  Src is known to regulate several pathways in the cell 
including the Erk1/2 pathway, found in the previous chapter of results to be activated by the 
pemetrexed/sorafenib drug combination.  Overexpression of dnSrc was shown to suppress drug-
induced activation of (phospho)-Erk1/2 in parental MCF7 cells (Figure 5-5A), whilst 
overexpression of a dominant negative form of MEK1 (dnMEK1) was shown to inhibit Erk1/2 
phosphorylation in these cells (Figure 5-5B).  dnMEK1 overexpression led to a significant 
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reduction in pemetrexed/ sorafenib-enhanced cell lethality in BT474, MCF7, and MCF7F cells 
(Figure 5-5C). 
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Figure 5-5:  Src regulates an Erk1/2-mediated response to pemetrexed/ sorafenib in 
mammary carcinoma cell lines.  Cells were plated in media containing dialyzed serum and 
cultured for 24 hr prior to transfection with control plasmid or a plasmid to express a dominant-
negative form of MEK1.  Per western blot analysis: (A) Upon overexpression of dnSrc, 
activation of ERK1/2 is reduced for pemetrexed/ sorafenib co-treatment samples, as compared to 
vector control transfected in MCF7 cells.  (B) dnMEK1 overexpression in these cells results in a 
suppression of ERK1/2 activation.  (C) Overexpression of dnMEK1, when compared to vector 
control transfected cells, causes a significant reduction in drug combination-induced cell 
lethality# (p<0.05) in BT474, MCF7, and MCF7F cells, when compared to their respective vector 
controls. 
 
 
The amount of autophagic vesicle formation was examined in MCF7F cells overexpressing 
dnMEK1, to determine whether activation of Erk1/2 by MEK1 is also necessary for drug-
induced activation of autophagy.  Overexpression of dnMEK1 elevated the basal levels of early 
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autophagic vesicle formation.  However, overexpression of dnMEK1 was shown to suppress the 
pemetrexed/ sorafenib-induced enhancement in LC3+ vesicle formation; more so at the 12 hr 
time point than the 24 hr time point, possibly due to upregulation of TS in a compensatory effort 
to reestablish normal DNA synthesis levels (Figure 5-6).  A similar effect was noted for BT474 
and MCF7F cells overexpressing dnMEK1 when examining late-stage endosomal activity using 
Lysotracker Red staining.  The increase in endosomal acidification caused by pemetrexed/ 
sorafenib cotreatment was reduced in cells overexpressing dnMEK1 (Figure 5-7). 
 
 
 
Figure 5-6:  Overexpression of a non-functional form of MEK1 attenuates activation of 
autophagy in pemetrexed/ sorafenib-treated cells.  Cells were plated in media containing 
dialyzed serum and cultured for 24 hr prior to transfection with vector control plasmid or a 
plasmid to overexpress a dominant-negative form of MEK1.  (A) Overexpression of dnMEK1 
reduces the levels of autophagosome formation resultant of combination treatment with 
pemetrexed and sorafenib in MCF7F cells, as compared to vector control transfected cells# 
( p<0.05 less than CMV control cell sample values). (B) Overexpression of dnMEK1 reduces the 
toxic side effects of pemetrexed/ sorafenib co-treatment, as compared to vector control 
transfected cells for MCF7F and BT474 cell strains# ( p<0.05 less than empty vector (CMV) 
value). 
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Figure 5-7:  Overexpression of dnMEK1 suppresses drug combination-induced acidic 
lysosome formation.  Cells were plated in media containing dialyzed serum and cultured for 24 
hr prior to transfection with vector control plasmid or a plasmid to overexpress a dominant-
negative form of MEK1.  Overexpression of dnMEK1 reduces the levels of acidic lysosome 
formation in MCF7F (left) and BT474 (right) cells, as compared to vector-transfected and 
vehicle-treated controls. 
 
 
Collectively, the data presented here demonstrates that down-regulation of PDGFRβ promotes 
the activation of Src Tyr416 and subsequent phosphorylation of Erk1/2 by MEK1, through a 
mechanism unidentified as of yet.  Each of these signaling components is important for induction 
of autophagy-dependent cellular toxicity in the breast cancer cell models used in this study.  
MEK/Erk signaling is generally associated with pro-survival events, however, some studies have 
shown that Erk1/2 activation can coincide with cell death, as it does in this particular 
combination therapy response.  There are several levels of enzymatic control exerted over the 
Erk1/2 pathway including other kinases, as well as protein phosphotases, namely PP2A. For this 
reason, we assessed whether PP2A plays a role in Src-Erk1/2-mediated drug combination 
lethality in the breast cancer cell models used in this study. 
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5.5 Protein phosphatase PP2A is involved in the cytotoxic response of parental and Fulvestrant-
resistant MCF7 cells to pemetrexed/ sorafenib treatment 
 
Protein phosphatases serve as important regulators of intracellular signaling cascades.  Protein 
phosphatase 1 (PP1) and protein phosphatase 2A (PP2A) account for approximately 90% of 
serine/threonine phosphatase activity in most mammalian cells and have been shown to regulate 
nearly all cellular events (311).  PP2A is promiscuous for a wide variety of protein substrates 
owing to a dynamic relationship within its tri-subunit holoenzyme complex, which delegates 
specific binding to regulatory molecules and proteins (312).  These interactions mediate function 
through sub-cellular localization to specific compartments within the cell for specific targeting to 
downstream effector proteins.  PP2A is known to have numerous downstream targets which 
enable its involvement in almost all cellular events, both pro-survival or pro-apoptotic.  
Attenuation of PP2A activity has been linked to increased tumorigenicity in cancer cells, 
suggestive of the theory that PP2A functions as a tumor suppressor (311-312).  PP2A is 
regulated by endogenous inhibitory proteins, inhibitor 1 of PP2A (I1PP2A) and inhibitor 2 of 
PP2A (I2PP2A/SET) (313).  These inhibitors act noncompetitively to regulate PP2A depending 
on its sub-cellular localization.  I2PP2A expression has been linked to tumorigenicity in NSCLC, 
leukemia, prostate cancer, and breast cancer cells (313-315).  For this reason, it is important to 
take into consideration the changes in I2PP2A levels when evaluating PP2A activity and the 
levels of Erk1/2 phosphorylation regulated by PP2A. 
 
Based on previous data in this study suggesting that fulvestrant-resistant MCF7F cells express 
higher basal levels of Erk1/2 activity and previous reports that describe MCF7F cells as being 
more aggressive than parental MCF7 cells, we next we determined the possibility that 
phosphatases have a role in the mechanism by which these drug acheive their toxic effect.  We 
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began by evaluating PP2A activity, while this phosphatase is reported to play a role in many 
chemotherapeutic drug interactions.  Our data showed that PP2A mediates pemetrexed/ 
sorafenib- induced Erk1/2 activation and tumor cell toxicity.  The manipulation of I2PP2A 
expression as a means of down-regulating PP2A activity was performed in the following 
experiments.  MCF7F cells express higher SET/ I2PP2A levels than MCF7 cells, whilst I2PP2A 
expression was shown to increase for both cell lines when treated with pemetrexed and sorafenib 
(Figure 5-8A).  Basal levels of PP2A activity are higher in parental MCF7 cells than fulvestrant-
resistant MCF7F cells.  Treatment of MCF7F cells with pemetrexed and sorafenib resulted in an 
approximate 2-fold enhancement in PP2A activity, which was negated by overexpression of 
I2PP2A (Figure 5-8B).  As previously noted, MCF7F cells have higher basal expression of 
Erk1/2 activity (Figure 5-8C).  Overexpression of I2PP2A in MCF7F cells resulted in an increase 
in basal Erk1/2 activity, whilst treatment with pemetrexed and sorafenib did not result in any 
further change in phospho-Erk1/2 expression (Figure 5-8D).  Thus, drug-induced activation of 
Erk1/2 is likely required for drug-induced killing. Cell killing is not simply induced by a cell 
exhibiting elevated Erk1/2 activity.  Collectively these findings argue that PP2A activity status 
can be manipulated by overexpression of I2PP2A and that its activity regulates Erk1/2 signaling 
in pemetrexed/ sorafenib-treated breast cancer cells. 
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Figure 5-8:  PP2A is activated in response to pemetrexed/ sorafenib cotreatment in MCF7F 
cells.  Cells were plated in media containing dialyzed serum and cultured for 24 hr prior to 
transfection.  36 hr after transfection, cells were treated with vehicle or the drug combination.  
Parent and fulvestrant-resistance MCF7 cells were treated with vehicle or pemetrexed (1µM) + 
sorafenib (3µM) for 24 hr, lysates harvested, then expression levels were evaluated using 
immunoblotting techniques or PP2A activity quantified.  All protein levels were normalized to 
GAPDH, then quantified to represent –Fold change in protein levels.  (A) The levels of I2PP2A 
increased upon treatment with Ptx and Sor, as compared to basal levels in vehicle-treated cells* 
(p<0.05)  MCF7F cells express higher basal levels of I2PP2A than the parental strain% (p<0.05)  
(B) Basal PP2A activity was evaluated in MCF7 and MCF7F cells and quantified to represent –
Fold change in activity.  PP2A activity was approximately 2-fold greater in MCF7F cells¶ 
(p<0.05).  Treatment of MCF7F cells with Ptx and Sor caused a 2-fold enhancement in PP2A 
activity, as compared to vehicle treated cells¶¶ (p<0.05).  Overexpression of I2PP2A suppressed 
the enhancement of PP2A activity caused by drug combination treatment¶¶¶ (p<0.05).  (C) 
MCF7F cells express much higher basal levels of P-ERK1/2, than do MCF7.  (D) In MFC7F 
cells, treatment with Ptx and Sor enhances the levels of P-ERK1/2* (p<0.05).  Overexpression of 
I2PP2A in these cells results in higher basal levels of p-ERK1/2% (p<0.05) however it prevents 
the increase in P-ERK1/2 caused by drug combination treatment.  
 
 
The impact of I2PP2A expression on drug-induced autophagy and cell killing was investigated. 
Overexpression of I2PP2A was shown to reduce drug combination-induced enhancement of 
autophagic vesicle formation, as well as drug combination toxicity in MCF7F cells (Figure 5-9A-
B).  Thus, overexpression of I2PP2A, causing a decrease in PP2A activity, is able to protect 
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breast cancer cells from pemetrexed/ sorafenib-induced cell lethality indicative of the theory that 
PP2A may be involved in drug combination-enhanced cellular toxicity. 
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Figure 5-9:  Overexpression of I2PP2A suppresses drug-induced autophagy and toxicity in 
MCF7F cells.  Cells were plated in media containing dialyzed serum and cultured for 24 hr prior 
to transfection with a vector control plasmid or plasmid to overexpress I2PP2A.  36 hr after 
transfection, cells were treated with vehicle or pemetrexed (1µM) and sorafenib (3µM) for the 
indicated times.  (A) Western blot analysis verifying overexpression of I2PP2A in MCF7F cells 
(upper).  Overexpression of I2PP2A suppresses drug combination-induced autophagic vesicle 
formation at 12 and 24 hr time points# (p<0.05 less than corresponding value in CMV vector 
control-transfected cells).  (B) Pemetrexed/ sorafenib treatment causes an enhancement in cell 
death* (p<0.05) which is abolished upon overexpression of I2PP2A¶ (p<0.05 less than 
corresponding value in CMV vector control-transfected cells).  
 
 
Collectively, these findings strongly suggest that PP2A activity is a factor in pemetrexed/ 
sorafenib-induced cytotoxicity in mammary carcinoma cells, based on overexpression of I2PP2A.  
One avenue of investigation for enhancement of PP2A activity resulting from combination drug 
therapy involves the generation of bio-active lipids, such as ceramides.  In recent years, I2PP2A 
was found to interact with ceramides, preventing its inhibitory association with PP2A. The PP2A 
heterotrimer itself also has been shown to interact with ceramide, with ceramide promoting 
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PP2A activation.  These phenomena were found to occur in multiple tumor types, arguing for a 
tumor suppressive role for PP2A (208).  Because PP2A activity was shown to promote drug 
combination sensitivity in the tumor models used in this study, we theorized that ceramide levels 
may also be elevated in these cells as a result of drug-induced cellular stress. 
 
5.6 Drug combination interactions in breast cancer cells are ceramide-dependent 
 
To determine if PP2A activation was ceramide-dependent, we first examined whether loss of 
ceramide synthase 6 (LASS6), the enzyme responsible for de novo ceramide synthesis of 16 
carbon (C16) lipids, could alter drug combination-enhanced PP2A activation.  Knockdown of 
LASS6 in MCF7F and BT474 cells blocked the enhancement of PP2A activity caused by 
pemetrexed/ sorafenib treatment (Figure 5-10). 
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Figure 5-10:  Knockdown of LASS6 abolishes drug combination-induced activation of 
PP2A in breast cancer cells.  Cells were plated in triplicate with media containing dialyzed 
serum and cultured for 24 hr prior to transfection with control siRNA or siRNA specifically 
targeting LASS6.  36 hr after transfection, cells were treated with vehicle or pemetrexed (1µM) 
and sorafenib (3µM) for 12 hr.  Lysates were collected and PP2A activity was evaluated.  
Activity values were quantified by cell number for each sample, which agreed with GAPDH 
normalization values, then represented as –Fold change in activity.  Treatment of MCF7F and 
BT474 cells caused a significant increase in PP2A activity at 12 hr* (p<0.05).  Knockdown of 
LASS6 significantly reduced drug combination-induced enhancement of PP2A activity in these 
cells** (p<0.05). 
 
 
Studies were performed to determine if pemetrexed/ sorafenib treatment caused an increase in 
ceramide and dihydroceramide levels in breast cancer cells.  In BT474 cells, co-treatment with 
these drugs increased the levels of C16:0, C22:0, C24:1, and C24:0 dihydroceramides (Figure 5-
11). The increase in dihydroceramide levels was reduced for C16:0 upon knockdown of LASS6. 
However, the increases in C22:0, C24:1, and C24:0 levels that occur as a result of drug 
combination treatment, were not altered by reducing the expression of LASS6 (Figure 5-11).  
The levels of C16:0, C22:0, C24:1, and C24:0 ceramides were not significantly altered by 
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treatment with pemetrexed/ sorafenib or by knockdown of LASS6 in the cells used in this study 
(Figure 5-11). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*
** 
 *
**
*
*
*
 
 
 
 
 
Figure 5-11:  The de novo ceramide synthesis pathway plays a role in the toxic interaction 
of pemetrexed and sorafenib in BT474 cells.  Cells were plated in triplicate with media 
containing dialyzed serum and cultured for 24 hr prior to transfection with control siRNA or 
siRNA specifically targeting LASS-6.  36 hr after transfection, cells were treated with vehicle or 
pemetrexed (1µM) and sorafenib (3µM) for 24 hr.  Lysates were harvested and samples 
evaluated for ceramide levels using an HPLC-MS-MS analysis method.  Values were normalized 
by cell number, which was verified by immunoblotting for GAPDH levels, then levels were 
quantified according to known standard concentration levels.  Western blot analysis verifying the 
knockdown of LASS6 in BT474 cells (upper panel).  Analysis of vector control versus si-LASS6 
samples, when treated with vehicle or drug combination, yielded no significant variations is 
ceramide levels (bottom, left panel).  Evaluation of the levels of dihydro-ceramides were all 
elevated as a result of pemetrexed/ sorafenib treatment* (p<0.05), however in the case of 16:0 
dihydroceramide, knockdown of si-LASS6 suppressed combination drug-induced di-hydro-
ceramide generation (bottom, right panel)** (p<0.05).  Raw data for ceramide and 
dihydroceramide levels were obtained by Jeremy Allegood of the Lipidomics/ Metabolomics 
Facility at VCU. 
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The data presented here suggests that PP2A activity is enhanced in breast cancer cells treated 
with pemetrexed/ sorafenib and that it may be in part responsible for drug-induced autophagy 
and cell death.  These findings also suggest that PP2A activity is dependent upon ceramide 
production and that C16:0 dihydroceramides levels are regulated by LASS6, which was found to 
likely play a role in the cytotoxic interaction of these drugs.  Together, these findings suggest 
that there may be a link between PP2A activity and the generation of dihydroceramides, which 
are both conducive for a toxic form of autophagy caused by co-treatment of breast cancer cells 
with pemetrexed and sorafenib. 
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Chapter 6: Discussion 
 
 
 
Pemetrexed, a second generation anti-folate drug approved for the treatment of malignant pleural 
mesothelioma and advanced or metastatic NSCLC, was reported to induce autophagy in tumor 
cells by causing an increase in intracellular ZMP+ levels that lead to stimulation of AMPK.  
AMPK activation leads to inhibition of mTOR and promotion of early autophagic vesicle 
formation (243-244,249).  No specific role for autophagy, whether pro-survival or pro-death was 
identified for pemetrexed-treated tumor cells in these studies.  Studies in this thesis aimed to first 
address the role of autophagy in response to pemetrexed exposure in multiple cancer cell types.  
Data indicated that in H460 NSCLC cells, pemetrexed treatment caused an increase in 
autophagic vesicle formation and that drug-induced enhancement of autophagy correlates with a 
dose-dependent decrease in cell viability.  Knockdown of Beclin1 or pre-treatment of the cells 
with 3-MA to inhibit formation of the autophagosome attenuates these effects.  These results 
were also noted in 4T1 and BT474 mammary carcinoma cells, as well as HuH7 human hepatoma 
cells.  Together, these data illustrate that pemetrexed lethality is dependent on a cytotoxic form 
of autophagy in multiple tumor types.   
 
These findings may in part be explained by pemetrexed induced inhibition of a secondary target 
AICART, the second folate-dependent enzyme in the de novo purine biosynthetic pathway which 
catalyzes the conversion of ZMP+ (AICAR) into formyl-AICAR.  Inhibition of AICART results 
in intracellular accumulation of ZMP+, a substrate for this reaction known to cause ER stress 
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resulting in activation of the AMPK pathway for the purpose of restoring cellular homeostasis.  
Activation of AMPK leads to the inhibition of mTOR.  mTOR is universally accepted to be the 
gatekeeper for autophagic cellular responses through its interactions with Akt and AMPK 
pathway members.  Inhibition of mTOR enables the association of ATG proteins, which is 
necessary for formation of the autophagosome.  Autophagy can be utilized as a mechanism by 
which the cell recycles its components to restore homeostasis in the cell or in some cases, as a 
means to cell death.  In these studies, treatment of tumor cells with pemetrexed resulted in the 
latter, thus providing an explanation as to the mode of drug lethality (Figure 6-1). 
 
Based on work in our laboratory and others, we hypothesized that sorafenib, a relatively 
promiscuous RTK inhibitor known to also induce a cytotoxic form of autophagy, may interact 
with pemetrexed in a manner which enhances pemetrexed cytotoxicity in these tumor cells (284-
287).  Our lab reported in earlier studies that combining sorafenib with vorinostat further induced 
vorinostat cytotoxicity in gastrointestinal cancer cells that was dependent on ceramide generation 
resultant of CD95 and PERK activation (181,202,315-317,316-318).  In H460 NSCLC cells, co-
treatment with pemetrexed and sorafenib at concentrations well below the maximal achievable 
dose for each caused a dose-dependent enhancement of autophagy which corresponded with a 
dose-dependent increase in cell death.  Combination drug treatment elucidated similar effects in 
breast and hepatic carcinoma cell models.  We also tested the effectiveness of pemetrexed/ 
sorafenib co-treatment in several breast cancer cell types of variable lineages, to determine if this 
combination therapy was effective in, both, Her2+ (SKBR3, BT474) and estrogen-independent 
triple negative (BT549, HCC1187, HCC1937) breast tumor cells.  All breast cancer cell lines 
demonstrated a dose-dependent increase in cell death when treated with pemetrexed and 
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sorafenib at variable concentrations, BT549 cells required a higher dosage to achieve the same 
lethal effect.  Taken together, these data support the notion that pemetrexed/ sorafenib co-therapy 
is effective in the treatment of both ER+ and triple negative mammary carcinoma cells. 
 
Acquired drug resistance as a result of developing estrogen independence is a major obstacle in 
the treatment of breast cancer patients undergoing continued drug treatments.  Faslodex 
(fulvestrant) has proven beneficial for the treatment of ER+ metastatic breast cancer in post-
menopausal patients who had been previously been treated with tamoxifen then become resistant.  
This effect is likely due to the distinct mode of action by which fulvestrant inhibits estrogen 
signaling (298-299).  Fulvestrant is typically issued as a second-line therapy, in breast cancer 
patients who have developed a resistance to a first-line chemotherapeutic regimen, whilst there 
are many patients that will also develop a resistance to fulvestrant (299-300).  MCF7 is a well-
characterized ER+ mammary ductal epithelial cell line isolated from a pleural effusion of a post-
menopausal woman (301).  Nephew and colleagues developed a fulvestrant-resistant MCF7 
model (MCF7F) through stringent selection of cells able to bypass estrogen-dependence after 
exposure to 1 µM fulvestrant for 18 months (302).  MCF7F cells are known to express higher 
levels of EGFR and breast cancer resistance protein (BCRP) than their parental counterparts.  
For this reason, we compared the drug combination sensitivities of parental MCF7 to fulvestrant-
resistant MCF7F cells.  We found that cell death was enhanced in both cell lines in a greater than 
additive fashion, when compared to individual drug treated cells, MCF7F cells were more 
sensitive to the drug combination. 
 
In an attempt to elucidate the biochemical mechanisms by which these drugs interact, as well as 
to further characterize the mechanisms by which fulvestrant-resistant MCF7F cells are more 
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responsive to pemetrexed/ sorafenib cotreatment, studies were undertaken to compare the 
expression patterns of autophagy-related proteins for estrogen-dependent and fulvestrant-
resistant MCF7 cells.  It is well accepted that many primary breast cancers including MCF7 cells, 
express a haplotype of Beclin1 that leads to an insufficiency of the protein causing these cells to 
be less effective at inducing autophagy than non-transformed mammary epithelial cells (303).  
Parental MCF7 cells were compared to fulvestrant-resistant MCF7F cells which are no longer 
responsive to estrogen.  MCF7F cells expressed higher basal levels of autophagy-related proteins 
(Beclin1, ATG5-12, LC3II, p62) than parental MCF7 cells.  Both, MCF7 and MCF7F cells, 
demonstrated an increase in the levels of Beclin1 when treated with individual drugs which was 
further enhanced by drug combination. The levels of ATG5-12 and LC3II were also enhanced in 
both cell lines when treated with individual drugs and the drug combination.  In agreement with 
these findings, the levels of p62 were reduced in both cell lines when treated with the drug 
combination, demonstrating that autophagy was progressing to the late stage endosomal state 
where p62 becomes enzymatically cleaved for recycling of amino acids.  Higher basal expression 
of autophagy related proteins suggests that a protective form of autophagy may be occurring as a 
result of biochemical changes made within the cell to establish estrogen independence.  In 
comparison to parental MCF7 cells, MCF7F cells also expressed higher basal levels of protective 
Mcl-1 and Bcl-XL proteins, this may further explain how MCF7F cells engage in a protective 
form of autophagy basally.  However, when treated with the drug combination, MCF7F cells 
demonstrated a significantly greater reduction in the levels of Mcl-1 and Bcl-XL, which may 
suggest an explanation as to how these cells are more sensitive to pemetrexed/ sorafenib co-
therapy.  In summation: the expression patterns of protective Bcl-2 family member proteins, as 
well as proteins involved autophagy, suggest that MCF7F cells demonstrate higher basal levels 
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of autophagy, which may exist as a result of a protective effort to maintain a natural energy and 
nutrient state resultant of biochemical changes that have occurred as a result of establishing 
estrogen independence.  The level of autophagy-dependent protein expression were enhanced in 
both cells lines when treated with the pemetrexed/ sorafenib combination, whilst the levels of 
protective Mcl-1 and Bcl-XL proteins were significantly reduced in MCF7F cells.  These 
findings suggest that the enhanced induction of autophagy in MCF7F cells exists as a protective 
means of maintaining cellular homeostasis post-establishment of estrogen independence, and that 
drug combination induced changes in protective Bcl-2 family members and autophagy related 
proteins and may in part explain why these cells are more sensitive to the drugs than their 
estrogen dependent counterparts.  
 
Autophagy and the intrinsic apoptosis pathway are inter-connected processes.  These pathways 
have been reported to interact to alter cell viability during ER stress caused by ROS generation in 
the cell.  There are multiple means by which intracellular generation of ROS and ER stress can 
promote cell death.  One of the best characterized mechanisms of ROS-stimulated cell death 
involves protein kinase RNA-like endoplasmic reticulum kinase (PERK) (202).  PERK 
phosphorylates eukaryotic initiation factor 2α (eI2Fα), which attenuates transcription leading to a 
reduction in translation of protective Bcl-2 family member proteins, namely Mcl-1, thereby 
enabling Beclin1 to carry out its role in initiation of autophagosomal membrane formation 
(202,318-320).  Treatment with pemetrexed and sorafenib was shown to cause a reduction in 
Mcl-1 and Bcl-XL protein expression, as well as an increase in the levels of Beclin1 
unsequestered by these protective BH3-domain containing proteins in parental and fulvestrant-
resistant MCF7 cells.  The roles of extrinsic apoptosis, intrinsic apoptosis, and autophagy were 
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assessed in our combination treated cells.  Overexpression of c-FLIP-s in MCF7 and MCF7F 
cells did not significantly alter drug combination induced toxicity, overexpression of a dominant-
negative form of caspase-9 or protective Bcl-XL reduced pemetrexed/ sorafenib toxicity in these 
cells.  These results suggested that pemetrexed/ sorafenib induced cell killing was not dependent 
upon the extrinsic apoptotic pathway, rather a mitochondria dependent mechanism.   
 
To determine the mechanisms by which pemetrexed/ sorafenib treatment propagates a cytotoxic 
death signal in MCF7 and MCF7F cells, the activation status of several important protein kinases 
involved in cell survival and cell death by evaluating phosphorylation at their regulatory sites 
was examined.  MCF7F cells express higher basal levels of protein expression of activated p70 
S6K and mTOR than parental MCF7 cells, as well as demonstrating a more significant reduction 
in activation of these proteins when treated with pemetrexed and sorafenib.  Knockdown of p70 
S6K and mTOR in MCF7F cells exhibited a greater enhancement of cell death when treated with 
the pemetrexed/ sorafenib combination than did parental MCF7 cells.  These results are in 
agreement with the initial observations suggesting MCF7F cells were more sensitive to drug 
combination treatment.  Likewise, overexpression of constitutively active forms of p70 S6K or 
mTOR resulted in a decrease in drug combination induced cell death in MCF7 and MCF7F cells.  
This data indicated that higher basal expression of p70 S6K and mTOR, as well as higher basal 
expression of activated p70 S6K and mTOR, may offer a survival advantage in breast cancer 
cells having established estrogen independence.  Akt activity is known to regulate both of these 
pathways, the levels of Akt phosphorylation were not significantly altered by pemetrexed/ 
sorafenib treatment in either cell line.  This may be explained by an increase in Erk1/2 
phosphorylation, as signaling through Erk1/2 has been linked to increased autophagy in several 
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different cell types (326-327,321-322).  Erk1/2 activation was enhanced in both parental and 
fulvestrant-resistant MCF7 cells treated with the drug combination, while it was found to be 
more significant in parental MCF7 cells.  This data suggested a complex mechanism by which 
these drugs interact to induce a cytotoxic response in breast cancer cells. 
 
A comparison of RTK expression levels for MCF7 and MCF7F cells demonstrated that MCF7F 
cells express higher basal expression of FGFR1 and PDGFRβ, both secondary targets of 
sorafenib.  These results suggested that these membrane receptors may be important targets for 
sorafenib in breast cancer cells at the concentrations used in the studies presented here.  The 
effects of PDGFRß knockdown in these cell lines were evaluated to determine the contribution 
of PDGFRβ in the toxic interactions of pemetrexed and sorafenib.  Treatment of MCF7 and 
MCF7F cells with pemetrexed post-knockdown of PDGFRβ enhanced cell death percentages in 
each cell line, suggesting that PDGFRβ might important target for sorafenib in these breast 
cancer cells.  MCF7F express higher basal levels of PDGFRβ, offering one possible rationale as 
to why these cells may be more sensitive than parental MCF7 cell to the pemetrexed/ sorafenib 
cotherapy. 
 
To summarize: MCF7F cells are more sensitive to pemetrexed/ sorafenib combination treatment 
than parental MCF7 cells. Data presented here offers several plausible explanations as to how 
this might occur.  First, MCF7F cells express higher basal levels of autophagy related proteins, 
likely as a protective effort in these cells.  However, when expression of these proteins is further 
enhanced by treatment with pemetrexed and sorafenib; the balance shifts in favor of a cytotoxic 
form of autophagy that leads to cell death.  MCF7F cells also express higher basal levels of 
protective Bcl-2 family member proteins, Mcl-1 and Bcl-XL, which correlates with the notion 
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that higher basal levels of autophagy serve to protect these cells under normal conditions.  Upon 
co-treatment with pemetrexed and sorafenib, MCF7F cells demonstrated a greater reduction in 
the levels of Mcl-1 and Bcl-XL, illustrating the possibility that these proteins may be key 
regulators of the shift from a cytoprotective to cytotoxic form of autophagy.  In addition, 
enhanced basal PDGFRβ expression levels may offer an explanation as to how MCF7F cells are 
more sensitive to treatment with pemetrexed alone or pemetrexed/ sorafenib cotreatment, as 
PDGFRβ appears to be a key target of sorafenib in these cells. 
 
In the second chapter of results, possible roles for Src, PP2A, I2PP2A, and de novo ceramide 
synthesis in the Erk1/2-dependent interaction of pemetrexed and sorafenib in mammary 
carcinoma cells were investigated.  Again, we show that pemetrexed and sorafenib co-therapy 
stimulated autophagy and cell death in breast cancer cells (BT474 and MCF7F), which was 
suppressed by knockdown of Beclin1.  Studies concerning the progression of early autophagic 
vesicles to the stage of the late endosome, where proteolytic degradation of autophagolysosome 
components takes place suggested that in both cell lines, treatment with pemetrexed and 
sorafenib enhanced late stage endosomal activity in a dose dependent manner.  This effect was 
shown to be suppressed by knockdown of Beclin1, this potentially indicated that an induction of 
early autophagosome formation was necessary for this response.  The requirement for acidic 
endosome acidification in this response was assessed by cell death analysis. Results indicated 
that inhibiting endosome acidification by treatment with NH4Cl completely abolished drug 
combination-induced toxicity in BT474 and MCF7F cells. 
 
According to an earlier study reported by our laboratory and others, sorafenib treatment can lead 
to inhibition of PDGFRβ and activation of Src, which in turn promotes activation of the CD95 
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death cell receptor and induction of the extrinsic apoptotic pathway (315-317).  In BT474 cells 
knocked down for PDGFRβ, led to an almost two-fold increase in p-Src Y416.  This led to the 
evaluation Src activation in the response of BT474 and MCF7F cells to pemetrexed/ sorafenib 
cotherapy.  When examining the formation of early autophagic vesicles in BT474 cells 
overexpressing dnSrc, it was found that Src was required for the pemetrexed/ sorefenib 
interaction in these cells.  Examination of Src Tyr416 phosphorylation in BT474 cells, when 
knocked down for PDGFRβ, indicated that Src activation is enhanced by a reduction in 
activation of PDGFRβ.  This have may occured as a result of Src becoming available to interact 
with an alternative upstream activator, possibly another RTK on the plasma membrane (Figure 6-
1).  Overexpression of dnSrc in MCF7F cells was shown to suppress drug combination-induced 
cell killing, suggesting that in Her2-negative cells, Src activation was also important for the 
pemetrexed/ sorafenib interaction.  Src interacts intra-cellularly with multiple RTKs,, Indeed, Src 
is well-documented to interact with EGFR/Her1 and Her2/neu receptors that are known to be 
overexpressed in 20-30% of breast cancer patients (323-324).  Other Src activating RTKs include 
FGFR1 and Met, these receptors also happen to be known secondary targets of sorafenib.  It is 
possible that inhibition of PDGFRβ releases Src from its interactions with this receptor, enabling 
Src interactions with other RTKs such as EGFR and Her2 through the aid of adaptor proteins.  In 
the case of BT474, which expresses both receptors and to overexpress Her2, Src may interact 
with either receptor to become activated and signal to downstream effectors to promote 
activation of the MEK/Erk pathway and enhancement of lipid metabolism.  In the case of 
MCF7F cells, which are Her2 negative, Src may still interact with EGFR to promote the same 
downstream signaling outcomes.  This is just one explanation as to the activation of Src in breast 
cancer cells where PDGFRβ signaling is inhibited as a result of pemetrexed/ sorafenib co-
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treatment, more specifically sorafenib treatment.  Src may also be activated by other RTKs as 
well as multiple cytoplasmic kinases upon treatment with pemetrexed and sorafenib. 
 
 An assessment of whether Src activation was required for MEK/Erk activation in the 
pemetrexed/ sorafenib response was performed.  Overexpression of dnSrc attenuated the drug-
induced levels of activated Erk in BT474 cells.  To further validate these signaling phenomena 
dnMEK1 was overexpressed in BT474, MCF7, and MCF7F cells. Results indicated that the 
lethal effects of co-treatment with pemetrexed and sorafenib were significantly reduced by the 
effects of overexpressing a non-functional form of MEK.  Overexpression of dnMEK1 in 
MCF7F cells was shown to reduce drug-combination induction of early autophagosome 
formation.  Overexpression of dnMEK1 also dramatically reduced late stage endosomal activity 
in these cells.  Together, these data suggest that Src may mediate activation of MEK/Erk which 
we found is strongly upregulated in breast cancer cells in response to pemetrexed/ sorafenib- 
treatment.  
 
Protein phosphatases are important modulators of signal transduction pathways.  PP1 and PP2A 
account for 90% of serine/ threonine phosphatase activity in mammalian cells.  Their activation 
is regulated by multiple protein signals, including the Src signaling network.  PP2A is know to 
be an important regulator of the Erk1/2 pathway and is thought to become less active as a tumor 
progresses to an advanced state.  We analyzed the role of PP2A in the Erk1/2-dependent 
interaction between pemetrexed and sorafenib in breast cancer cells by overexpressing I2PP2A, 
an inhibitory protein for PP2A.  Results indicated that MCF7F cells expressed higher basal levels 
of I2PP2A and phospho-Erk1/2 when compared to parental MCF7 cells, I2PP2A levels were 
enhanced in both cells lines when exposed to pemetrexed/ sorafenib co-therapy.  Based upon 
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evaluation of PP2A activity in these cells using a PP2A-specific activity assay kit, PP2A basal 
activity was determined to be greater in parental MCF7 cells when compared to MCF7F cells.  
This finding can at least in part be explained by the differences in I2PP2A expression levels in 
these cell lines.  Treatment of MCF7F cells with the drug combination caused an increase in 
Erk1/2 activation and PP2A activity, which was suppressed by overexpression of I2PP2A.  It is 
important to note that the basal expression of phospho-Erk1/2 in MCF7F cells was increased in 
response to overexpression of I2PP2A, while there was no further activation of Erk1/2 when the 
cells were treated with pemetrexed and sorafenib.  Overexpression of I2PP2A in MCF7F cells 
also led to a significant reduction in pemetrexed/ sorafenib-stimulated early autophagic vesicle 
formation and cell lethality.  PP2A activity was also shown to be altered during pemetrexed/ 
sorafenib-induced cell death for MCF7F cells. 
 
Many studies have reported that PP2A activity can be regulated by bio-active lipids, more 
specifically ceramides (177,179,181-183,186,189,196,198,200,208-209,294,325-326) (Figure 6-
1).  It is also well documented that Src activation can mediate lipid metabolism in breast cancer 
cells (324).  Having identified a clear role for PP2A activation in cellular response to 
pemetrexed/ sorafenib exposure, the importance of ceramide generation in regulating drug 
combination enhanced activation of PP2A was evaluated.  The de novo ceramide synthesis 
pathway can be responsible for activation of PP2A and induction of autophagy, LASS6 
generation of C16 dihydroceramides has also been identified in several studies as a key player in 
ceramide synthesis (202,327-328).  Results of the examination of PP2A activity in MCF7F and 
BT474 cells indicated that pemetrexed/ sorafenib-stimulated PP2A activation was significantly 
reduced by knockdown of LASS6.  Drug combination mediated enhanced PP2A activity 
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appeared to be more strongly reduced by knockdown of LASS6 in BT474 cells than in MCF7 
cells.  The proportions of C:16, C22:0, C24:1, and C24:0 ceramides and dihydroceramides were 
evaluated for drug treated BT474 cells knocked down for LASS6 using an adapted version of an 
established HPLC  Mass Spectroscopy method (329).  Normal ceramide levels were not 
significantly altered by knockdown of LASS6 or drug treatment Pemetrexed/ sorafenib treatment 
was shown to induce an increase in all dihydroceramide levels examined.  LASS6 knockdown 
led to a suppression of the drug induced enhancement of C16:0 dihydroceramide level, this was 
expected, since LASS6 is the de novo enzyme responsible for specifically generating this lipid.  
The observed increase in C22:0, C24:1, and C24:0 dihydroceramide levels caused by 
pemetrexed/ sorafenib treatment were not affected by inhibiting LASS6 expression.  Knockdown 
of LASS6 also led to suppression of drug combination stimulated formation of early autophagic 
vesicles and cell killing in BT474 cells.  Treatment of BT474 cells with myriocin, a small 
molecule inhibitor of serine palmitoyltransferase of the de novo synthesis pathway, effectively 
enhanced the suppression of drug-induced cell death.  These findings suggest that de novo 
ceramide synthesis is involved in the toxic interaction of pemetrexed/ sorafenib in breast cancer 
cells and that C16:0 dihydroceramimdes are somehow important in this response.  Other 
dihydrocermides may be critical for this response; however only C16:0 dihydroceramide 
generation by manipulating the expression of LASS6 was evaluated in this study.  Other de novo 
ceramide synthetic enzymes may have an effect similar to that of LASS6, however these 
enzymes were not specifically examined.  Together with previous data, it can be concluded that 
de novo ceramide synthesis is required for activation of PP2A and that this event is critical for 
induction of autophagy and cell death in breast cancer cells (Figure 6-1).  Several 
chemotherapeutic agents have been identified which cause upregulation of de novo ceramide 
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synthesis in co-ordination with cell death, for example: daunorubicin, cisplatin, etoposide, 
gemcitabine, camptothecin, and fludurabine (325-326).  Dihydroceramides may not themselves 
induce apoptosis, although earlier studies have suggested that a dehydrogenase becomes 
activated to promote generation of ceramides which promote apoptosis in these tumor cells (326). 
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Figure 6-1:  A working model of the mechanisms which promote cytotoxicity as a result of 
cotreatment of breast cancer cells with pemetrexed and sorafenib.  Pemetrexed inhibition of 
its secondary target, AICART, leads to an increase in intracellular ZMP+ levels to induce AMPK 
activation and subsequent inhibition of mTOR, thus promoting autophagy.  AMPK activation is 
known to induce de novo ceramide synthesis, while the mechanism by which this occurs is not 
known.  PP2A becomes activated as a result of the changes in dihydroceramide levels, which can 
be explained by several mechanisms.  Exposure of breast cancer cells to sorafenib was 
demonstrated to interfere with PDGFRβ activity, a known target for the drug, resulting in 
disruption of the PDGFRβ-Src interaction; therefore enabling an interaction between Src and an 
alternate RTK.  Src is hyperactivated by the alternate RTK and signaling is transduced through 
the MEK/ERK pathway.  Sorafenib enhances pemetrexed-induced toxic autophagy through a 
mechanism which has yet to be determined.  Together, pemetrexed and sorafenib, act in at least 
an additive fashion to promote cell lethality. 
 
 
In addition to these in vitro findings, an in vivo orthotopic model of breast cancer was generated 
using BT474. Results in this model system indicated that combination therapy with pemetrexed 
and sorafenib was able to suppress BT474 tumor cell growth in a greater fashion than individual 
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drugs alone.  The in vivo data correlated with increased levels of apoptosis, as well as reduced 
proliferation in these tumors.  In additional studies involving pemetrexed and sorafenib 
combination treatment, the same effect was seen using an in vivo orthotopic model of GBM6 
human glioblastoma cells stably expressing the luciferase gene.  GBM6-luciferase cells 
demonstrated a marked decrease in tumor cell growth, as well as an increase in overall survival 
for mice co-treated with the drugs when compared to individual drugs alone (31).  Sections from 
normal tissue/ organs were analyzed from both breast carcinoma and glioblastoma models and 
no deleterious effects were noted.  In vivo experiments supported the notion that combination 
treatment with pemetrexed and sorafenib was an effective combination therapy for the treatment 
of multiple cancer cell types. 
 
Collectively, the studies detailed in this dissertation illustrate the effectiveness of pemetrexed/ 
sorafenib co-therapy for the treatment of multiple tumor types.  Experimental results illustrated a 
clear role for a toxic form of autophagy in drug combination lethality.  In vivo, the drugs interact 
to significantly reduce tumor growth for orthotopic mammary carcinoma and glioblastoma mice 
models.  Development of estrogen independence as a result of acquired chemotherapeutic drug 
resistance appeared to play a role in the sensitivity of the breast cancer cell lines tested to 
pemetrexed/ sorafenib co-therapy.  These findings suggested that this combination treatment 
regimen may be an effective means of treating triple negative breast cancer patients who have 
received earlier treatments with drugs for which they are no longer responsive. 
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